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Colorectal adenocarcinoma is the fourth most common cancer diagnosed worldwide and 
is a significant cause of morbidity and mortality. This dissertation performed an 
exploratory RNA-sequencing analysis comparing gene expression between colon 
adenocarcinoma tissue and paired normal colon epithelium. After identification of a 
number of lncRNAs that were increased in expression in colon adenocarcinoma 
compared to normal colon epithelium, we aimed to validate the expression and 
investigate their function in vitro. Specifically, we focused on the lncRNA ZFAS1 and its 
association with epithelial-to-mesenchymal transition. 
These studies found the following: 
1. Seven candidate lncRNAs were identified from the exploratory RNA-sequencing 
analysis to be significantly increased in expression in colon adenocarcinoma, three of 
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which ZFAS1, GAS5, and PVT1 were found to be significantly increased in colon 
adenocarcinoma compared to paired normal colon epithelium as examined by laser 
capture microdissection. 
2. Both ZFAS1 and GAS5 are significantly increased in cytoplasm of cell lines compared 
to the nucleus, whereas PVT1 was more represented in the nucleus. As such there was 
significant knockdown of both ZFAS1 and GAS5 following transfection with siRNA. 
3. Knockdown of ZFAS1 leads to decreased proliferation and migration in colon 
adenocarcinoma cell lines. In contrast, knockdown of GAS5 did not lead to a change in 
proliferation. We focused our subsequent investigation on ZFAS1. 
4. ZFAS1 has a reciprocal relationship with miR-200b and miR-200c expression in vitro 
but not with three of the other experimentally verified miRNAs that bind ZFAS1. We 
also validated the functional effect of miR-200b and miR-200c mimics on decreasing cell 
migration. 
5. ZFAS1 knockdown is associated with the functional changes on cellular phenotype 
through decreasing ZEB1 expression through miR-200 signaling, causing a subsequent 
increase in the expression of the epithelial marker, E-cadherin, and a decrease in the 
expression of the mesenchymal marker, vimentin. 
These findings demonstrate an association between ZFAS1 and miR-200/ZEB1/E-
cadherin, vimentin signaling in EMT signaling in colon adenocarcinoma. In contrast to 
typical EMT signaling, ZFAS1 knockdown also leads to decreased cell proliferation 
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INTRODUCTION- COLON AND RECTAL CANCER 
 
a)  Epidemiology and diagnosis of colorectal cancer in the United States 
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the 
United States and is the third leading cause of cancer related deaths.1 In 2018, there were 
approximately 140,000 new cases of colon and rectal cancer in in the United States, and 
approximately 50,000 deaths from colon and rectal cancer combined. A majority of 
patients present with advanced stage (lymph node disease or distant organ metastasis), in 
whom the risk of recurrence is high and the overall prognosis is poor (Figure 1).1,2 The 
relative 5-year survival for stage I CRC, however, is 92%. The 5-year survival for stage 
IIA and Stage IIB are 87% and 63%. The 5-year survival for stage IIIA, Stage IIIB, and 
stage IIIC are 89%, 69%, and 53%, respectively. The 5-year survival for stage IV disease 
is 11%. Although screening for colon and rectal cancer has been shown to improve 
survival, many patients are still diagnosed with advanced stage disease at initial 
presentation (Figure 2).3 
In the United States, cancer staging is guided by the American Joint Committee 
on Cancer (AJCC)4 TNM staging. TNM refers to Tumor, Node, and Metastasis staging. 
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This indicates the degree of invasion into the bowel wall, the presence of lymph node 
involvement, and the presence of distant metastasis, respectively. Previously, the Duke’s 
classification system had been long used for colorectal cancer staging, which was 
subsequently modified to the Astler-Coller staging system.5,6 These staging systems align 
with that of the contemporary TNM system (Table 1). Accurate staging is essential for 
assessing patient prognosis and deciding on the most appropriate treatment regimen.  
 
b)  Molecular pathophysiology of colorectal cancer 
The underlying etiology of CRC is complex and heterogeneous, but here are three 
major types of colorectal cancer; sporadic, inherited, and familial. Furthermore, there are 
three major pathways of pathogenesis that underlie the development of colorectal 
adenocarcinoma, but overlap exists between these pathways in patients. They include 
chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island 
methylator phenotype (CIMP). 
The CIN pathway is commonly known as the adenoma-carcinoma sequence. 7,8 
This pathway consists of a number of progressive “genetic hits” in normal colon 
epithelium, to produce an adenomatous polyp, and which eventually leads to an invasive 
adenocarcinoma. Classical mutations in this pathway consist of mutations in genes and 
signaling pathways such as APC, KRAS, TP53, TGF-β and PIK3CA.7 This adenoma-





Figure 1. Temporal changes in 5-year overall survival for colon and rectal adenocarcinoma stratified by disease stage in the United 













Although there have been improvements in overall survival for colon and rectal adenocarcinoma over the different time periods, the 
survival for patients with regional or distant disease at diagnosis remains poor.  
Modified from: Siegel RL, Miller KD, Fedewa SA et. al. Colorectal cancer statistics, 2017. 2017;67:3 177-193 and Siegel RL, Miller 










Modified from: Sheets SSF. Colon and Rectum Cancer. Cancer Statistics: Statistical Summaries National Cancer Institute. 2015. 
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Table 1) AJCC 8th edition staging for colorectal cancer and alignment with Duke’s 














































































































Tis: Carcinoma in situ, T1: Invasion into submucosa, T2: Invasion into muscularis 
propria, T3: Invasion through muscularis propria, T4a: tumor invades through the visceral 
peritoneum, T4b: Tumor invades or is adherent to adjacent organs. N0: No lymph nodes 
metastasis, N1a one lymph node positive, N1b two-three lymph nodes positive, N1c: tumor 
deposits in subserosa, mesentery, N2a four to six lymph nodes positive, N2b: >7 lymph nodes 
positive. M1a: metastasis to one site of disease, M1b: metastasis to >2 sites, M1c: Metastasis to 
peritoneal surface alone or with another organ metastasis 
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progression of adenomas to invasive adenocarcinoma.10,11 In addition, recent gene editing 
based studies support this hypothesis which introduce progressive mutations through 
CRISPR-mediated gene editing to produce an invasive adenocarcinoma from normal 
intestinal organoids.12 In this study, only organoids derived from adenomatous tissue, and 
not from normal colon epithelium, could lead to the development of macro-metastasis in 
an in vivo model, which suggests that other signaling factors beyond that of mutations in 
classically associated genes are a major driver for metastasis. 
Microsatellite instability is involved in the pathogenesis of 15-20% of colorectal 
cancer.13 This pathway consists of mutations in the genes that are responsible for 
repairing base mismatches in cellular DNA. 14,15 In all cells, mistakes can occur in DNA 
replications which leads to the occurrences of mismatches between DNA base pairs. In 
cells with a normal mismatch repair system, this can be repaired to eliminate the 
mismatch, but in cells with a defective system, this repair does not occur and can lead to 
the progressive accumulation of mutations in genes. Most commonly, this occurs, 
through genes such as MLH1, MSH2, MSH6, or PMS2. The most commonly observed 
phenomenon amongst these genes is that of epigenetic silencing of MLH1 through 
promoter hypermethylation.16 Hereditary Non-Polyposis Colorectal Cancer, also known 
as Lynch syndrome, is a familial form of colorectal cancer, that occurs through an 
autosomal dominant germline mutation in one of the previously mentioned mismatch 
repair genes. 
Epigenetic modification of cells can occur through the methylation of CpG base 
residues. A CpG residue is the occurrence of a cytosine base adjacent to a guanosine base 
in DNA. In the promoter regions of genes, CpG residues can cluster into areas called 
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CpG islands which, when methylated, can lead to silencing of the gene.17 In the case of a 
tumor suppressor gene, this can promote carcinogenesis, even in the absence of a 
mutation within the gene sequence. The sessile serrated polyp pathway is thought to 
account for 20% of sporadic colorectal cancers. It shares a similar multi-hit pathogenesis 
as the CIN pathway, but is distinct in that KRAS and BRAF mutations are common, with 
the addition of the CpG island methylator phenotype to produce a microsatellite 
instability.18,19  
Although there are a distinct signaling pathways, as outlined above, an individual 
patient may have some elements of different pathways leading to colorectal cancer 
(Figure 3). Furthermore, there appears to be an association between the anatomical 
location and the spectrum of mutations of colorectal cancers. Right- sided colon 
adenocarcinoma tumors are more likely to be highly microsatellite instable tumors, 
whereas left-sided colon adenocarcinomas are more likely to be chromosomal instable 
tumors.20  BRAF mutations more commonly occur in colon adenocarcinomas, and rectal 
adenocarcinomas typically have APC and TP53 mutations.21 This adds to the complexity 





Figure 3. Schematic representation of several overlapping pathways involved in the development of colorectal cancer 
 
Red circles represent mechanisms based on tumor suppressor and mutator pathways. Blue circles represent mechanisms based on the 
precursor lesion (CIN and Serrated polyp pathways). Yellow circles represent currently poorly characterized pathways. 
MYH- mutY DNA glycosylase, TSA- Traditional serrated adenoma 
Snover DC. Hum Pathol. 2011;42(1):1-10
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c)  Contemporary treatment of colorectal cancer and current challenges 
Treatment for colorectal cancer is guided by the National Comprehensive Cancer 
Network in the United States.22 Surgical resection of the tumor is the principle treatment 
for colorectal cancer, which may be supported by other therapies including chemotherapy 
and radiotherapy depending on the tumor location and stage. In the case of advanced 
adenomas or early stage tumors, these may be amenable to local excision with 
endoscopy, or through transanal excision in certain cases.23  
Treatment strategies for advanced stage (Stage III or Stage IV) colon and rectal 
cancer are different in the case of neoadjuvant and adjuvant chemotherapy and 
radiotherapy. In the case of colon adenocarcinoma, adjuvant postoperative chemotherapy 
is recommended for advanced stage tumors or localized tumors with certain high-risk 
features (poor differentiation, lymphovascular invasion, perineural invasion, bowel 
obstruction, <12 lymph nodes examined, localized perforation, or close/positive 
margins). In the case of rectal adenocarcinoma, preoperative chemoradiotherapy is 
indicated for tumors beyond a T1-T2, N0 stage.9 Additionally, postoperative 
chemoradiotherapy may be indicated for high-risk cancers. For both colon and rectal 
adenocarcinoma, the chemotherapeutic agents that are used include 5-flurouracil, 
capecitabine, oxaliplatin, and irinotecan. However, advances in the understanding of 
tumor biology has led to the use of small molecule therapies which target specific 
signaling pathways involved in epidermal growth factor signaling (e.g. cituximab), 
vascular endothelial growth factor signaling (e.g. bevacizumab), or immune cell 
recognition of cancer cells (e.g. Nivolumab). 
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Surgical treatment for colorectal metastases can be carefully decided in a 
multidisciplinary fashion, as in the case of colorectal liver metastases24,25 or in colorectal 
lung metastases.26 As an adjunct to surgical resection, microwave coagulation therapy or 
radiofrequency ablation therapy can be considered. As metastatic disease is the principle 
disease-specific cause of death from colorectal cancer, it is important to study the process 
of how tumors transition from locally proliferative in the colon, to developing an ability 
to become metastatic. A critical aspect of this process is epithelial-to-mesenchymal 
transition, and improved understanding of this process may assist in the development of 


























EPITHELIAL-MESENCHYMAL TRANSITION IN CANCER 
 
a)  Introduction- Role in Normal Embryological Development and Cancer 
Epithelial-Mesenchymal Transition (EMT) is a cellular mechanism that has long 
been recognized as a central feature of normal cellular development.27 A number of 
important components of embryological development are reliant on EMT such as that of 
gastrulation, neural crest formation, and heart morphogenesis.28 Over the past 20 years, 
there has been significant research into the process of cancer metastasis and EMT has 
also been recognized to have a major role in its development.29  
 
b)  Role of EMT in Cancer 
EMT is the process whereby cells lose their morphological and functional 
epithelial features and gain a mesenchymal phenotype, through differential gene 
overexpression and repression 30,31. At a macroscopic level, this is the process whereby 
locally proliferative cancer growing in the bowel mucosa, gains the ability to invade from 
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the mucosa towards the bowel serosa, to the draining lymph nodes (Figure 4). At a 
cellular level, EMT is a complex process whereby epithelial-like cells lose cell polarity, 
cell-to-cell adhesion, and gain a migratory and invasive phenotype (Figure 5).32 This 
process consists of a series of molecular changes that are essential to occur to facilitate 
cancer metastasis.29,33 
There is clinical evidence to support that intra-tumoral differences exist in the 
expression of epithelial and mesenchymal markers.34 At the deep border of tumors in the 
wall of the colon there is relatively reduced expression of epithelial markers such as  E-
cadherin, occludins, and claudins,  and an increase in markers such a vimentin, N-
cadherin, and fibronectin.34,35 This indicates that cells which are at the deep border, or 
invasive front of a tumor have a more mesenchymal phenotype. Interestingly, EMT is 
reversed when cancer seeds, and develops at a metastatic site. Colorectal liver metastasis 
has been shown to recover epithelial marker expression and lose vimentin expression.36 
This reversion process is called mesenchymal-epithelial transition (MET) in cancer.  
There are a number of critical mediators of both EMT and MET in cancer, which affect 
these processes at both genetic and epigenetic levels. 
 
c)  Regulators of the EMT process through genetic and epigenetic processes 
Genetic regulation can occur through transcription factor regulation via factors 






Figure 4. Illustration of the macroscopic events of EMT that contribute to the change from a locally proliferative cancer to an invasive 
and metastatic cancer. 
 
As cancer cells grow locally, there is a switch to a mesenchymal phenotype and the deep border, which invades through the basement 
membrane to metastasize to the lymph nodes and in distant organs. At the new metastatic site, the cancer cells revert to an epithelial 
phenotype to proliferate. 
 
 
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation. 2009;119:1420-8.
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Figure 5. Illustration of the cellular events that contribute to the process of EMT to 
promote a metastatic cancer. 
 
There are a number of cellular changes that occur to change locally proliferative 
epithelial cells to more mesenchymal cells, which have the ability to migrate and invade 
through tissue.  
 
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal 




repressor 2 (SLUG), Zinc finger E-box-binding homeobox -(ZEB)1, and ZEB2.37,38 
These factors can directly induce the transcription of epithelial adhesion and cellular 
polarity genes and repress that of mesenchymal cytoskeletal and metalloproteinase genes.   
Epigenetic regulation of EMT can occur through different processes involved in 
methylation and acetylation.39,40 Methylation at CpG islands of the promoter region of 
genes involved in EMT repression has previously been demonstrated.41 Treatment with a 
demethylating agent has been shown to induce an epithelial-like phenotype in vitro in 
both naïve and chemoresistant cell lines.36,42  
 The field of non-coding RNA represents an expansive avenue of research for 
EMT, as both microRNA (miRNA) and long non-coding RNA (lncRNA) are significant 
mediators of this process.40,43 MicroRNAs (miRNAs) are a major regulator of cell 
function through specific interaction with RNAs to inhibit protein translation or to induce 
RNA degradation. miRNAs are small, naturally occurring, non-protein coding RNA 
molecules that are approximately 20 nucleotides in length. miRNAs are transcribed in the 
nucleus as large RNA precursors called primary microRNAs.44 They are processed in the 
nucleus and shuttled to the cytoplasm by the enzymes Drosha, exportin 5, DICER and 
argonaute 2. This produces mature double stranded microRNA.45,46 As miRNAs are 
normally occurring molecules, they perform several normal functions related to cell 
growth, development, and differentiation, but dysregulated expression of these 
microRNAs may contribute to tumorigenesis.47 Furthermore, altered expression of 
microRNAs in tumor tissue or serum may have a role in the diagnosis of patients with 
CRC.48,49 We have previously reported a panel of miRNA that were predictive of 
colorectal neoplasia in a large cohort of patients.50 
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The miR-200 family is one of the most well defined mediators of EMT, first 
reported by 2 separate research groups in 2008.30,31 The miR-200 family is a group of 5 
miRNA, that consists of 2 clusters determined by; functional grouping and by genomic 
location. miR-200a, miR-200b, and miR-429 are located on chromosome 1p36.33, and 
miR-200c and miR-141 are located on chromosome 12p13.31. In contrast, miR-200b, 
miR-200c, and miR-429 share the same seed sequence, whereas miR-200a and miR-141 
share the same seed sequence for functionality. The seed sequence is the part of the 
miRNA that confers specificity to a target mRNA sequence. There is a double-negative 
feedback loop between the miR-200 family and ZEB1/ZEB2 expression (Figure 6).31 The 
miR-200 family acts to decrease the expression of ZEB1 and ZEB2 through post-
transcriptional repression to mediate EMT. In addition, ZEB1 and ZEB2 act on the 
promoter region of the miR-200 family to transcriptionally repress miR-200 family 
expression. Decreased expression of the miR-200 family leads to a mesenchymal 
phenotype to promote EMT.30 TGF-β is a major regulator of EMT, through induction of 
ZEB1 and SNAI1 expression, which is also targeted by the miR-200 family to repress 
EMT.30,51 However, the miR-200 family has also been shown to induce proliferation 
through different signaling pathways such as through a miR-200/RECK/SKP2, CDKN1B 
axis and a miR-200/RASSF2/KRAS/ERK1,2 axis.52,53  
Multiple clinical studies have demonstrated that tumoral tissue expression of the 
miR-200 family is associated with worse clinical outcomes, such as reduced recurrence-
free survival54 and overall survival.55 However, there are conflicting individual results 
with respect to tissue and serum levels of the miRNA-200 family and these clinical 
outcomes.40   
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 lncRNAs are a recently described class of molecules that have a role in both 
normal cellular function and in tumorigenesis. They are another class of non-protein 
coding molecules that are defined as being greater than 200 bases in length.56 Similar to 
messenger RNA, they are transcribed by RNA polymerase II, but lncRNAs can mediate 
their action through a number of different mechanisms. 56,57 Specifically, they have been 
described to have been associated with EMT in a number of different cancers and as 
lncRNAs have a spectrum of mechanisms of action, they have the potential to be major 
















Figure 6. Representation of the reciprocal interaction between the miR-200 family and 
ZEB1, ZEB2 in EMT. 
 
There is a bidirectional repression between the miR-200 family and the transcription 
factors ZEB1 and ZEB2. Both of these factors, in addition to SNAIL1 and SLUG act to 
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LONG NON-CODING RNA AND ROLE IN COLORECTAL CANCER 
 
a) Introduction and history of non-coding RNA 
In the 1970s, evidence began to emerge to support the hypothesis that a large 
proportion of the human genome does not code for protein and was termed junk DNA. 
However, investigators began to note that although such DNA does not code for a 
protein, that does not mean it does not have a cellular function in some other capacity.58 
With the advent of sequencing technology, it is now understood that a large proportion of 
the genome is transcribed and warrants investigation to ascertain the function of such 
RNAs. There are a large number of non-coding RNAs currently described such as; 
ribosomal (r)RNAs, ribozymes, transfer (t)RNAs, small nuclear (sn)RNAs, small 
nucleolar (sno)RNAs, and telomere-associated RNAs (TERC, TERRA) microRNAs 





More recently, long-noncoding RNAs (lncRNA) have been a topical area of 
investigation, as they have been shown to have a role in a variety of aspects of normal 
cellular function and in disease.60 Some lncRNAs were described prior to the era of RNA 
sequencing such as XIST (X-inactive specific transcript).61 XIST was initially described 
as having the function of inactivating and transcriptionally silencing one of the X 
chromosomes in females. However, it has also been noted that XIST has a major function 
beyond this, in other areas of disease.59,62 
b) Mechanisms of action of long non-coding RNA 
Long non-coding RNA can be classified by their genomic location or by their 
molecular function.59 By location, lncRNAs can be classified as; sense, antisense, 
intronic, intergenic, or bidirectional in nature (Figure 7).57 By their molecular function, 
lncRNA have diverse mechanisms of action (Figure 8)56 which include: 
1) Competitive endogenous RNA function - the lncRNA acts as a functional 
decoy or “sponge” for other molecules, which prevents these molecules from 
executing their function, such as in the case of lncRNA-miRNA sponging; 
 2) Enhancer function- the lncRNA can act as an enhancer or transcription 
factor-like molecule in cells to promote gene expression;  
3) Scaffold function- the lncRNA can act to bring proteins spatially close to each 
other to aid in ribonuclear protein formation;  
4) Guide function- the lncRNA can recruit proteins to a nuclear site such as 
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Figure 8. Description of lncRNAs by their molecular function 
 
 
a) Signal mechanism- lncRNA can act to recruit other molecules to an area in the genome 
to perform an action. b) Decoy/competitive endogenous RNA mechanism- lncRNA can 
act to bind to another molecule which can prevent the target molecule from performing 
its action, c) Guide mechanism- lncRNA can bind other molecules and guide them to a 
location to perform their function, d) Scaffold mechanism- lncRNA can bind a number of 
molecules to bring them close together to perform their function, as in the case of 
transcriptional activators, e) Enhancer mechanism- lncRNA can modulate the interaction 
between enhancers or promoter regions of genes in chromosomal looping. 
Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, et al. Long 




c)  Role of lncRNA in colorectal cancer 
lncRNAs have been shown to have a major role in colorectal cancer pathogenesis 
in the literature. In particular, lncRNAs have been shown to mediate an effect on EMT 
and have a potential role as a biomarker. A review of the literature identified that 
lncRNAs act on a number of different signaling cascades; ZEB1,2/ E-cadherin, Vimentin, 
Wnt/β-catenin signaling, chromatin remodeling and epigenetic modulation, JAK-STAT3 
signaling, mTOR signaling, MAPK/ERK signaling, and TGF-β signaling among others 
(Figure 9). 
 
ZEB1,2/ E-cadherin, Vimentin signaling 
The ZEB1, 2/E-cadherin, Vimentin axis is a well characterized signaling pathway, 
critical to the process of EMT, and a number of different lncRNAs have been shown to 
affect this pathway. As previously mentioned, the miR-200 family is a major regulator of 
EMT by targeting ZEB1 and ZEB2. A number of the included studies identified lncRNAs 
which target the miR-200 family: XIST, N-BLR, and H19, the expression of which are 
increased in colon cancer and which are associated with adverse clinical outcomes.63-68 In 
addition, N-BLR mediates chemoresistance in vitro, highlighting the potential role of 






Figure 9. Role of lncRNAs in EMT in colorectal cancer 
 
The lncRNAs and their target molecules are organized by signaling pathways via different colors. The lncRNAs are highlighted                   
indicating a transcriptional factor regulation mechanism, highlighted                 for a lncRNA/miRNA molecular decoy mechanism, and 
highlighted                    for a scaffold mechanism.  
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Although the miR-200 family is most commonly known to be associated with this 
pathway, a number of other studies demonstrate a direct binding with other miRNAs in a 
competitive endogenous RNA mechanism. Both SNHG6 and SPRY4-IT1 target miR-
10169-71, HCP5 targets miR-139,72 while all three subsequently target ZEB1 and directly 
mediate EMT. This demonstrates the complexity of manipulating lncRNA in vitro as the 
effect on other lncRNA within a pathway has been poorly studied. Similar to these 
studies, UICLM targets miR-215, which in turn targets ZEB2 in the signaling cascade.73 
Interestingly, B3GALT5-AS1 is a lncRNA which targets the transcription factors ZEB1 
and SNAIL through a competitive endogenous RNA mechanism by binding miR-203.74 
However, unlike the previously mentioned lncRNA, B3GALT5-AS1 is decreased in 
colorectal cancer compared to normal colorectal epithelium. SLUG is another major 
regulator of EMT, which activates SNAIL. The lncRNA SNHG15 inhibits the 
degradation of SLUG by preventing its ubiquination.75 TWIST1 is another well-
characterized molecule that regulates EMT. CHRF is an lncRNA that targets TWIST1 by 
targeting miR-489.76 These studies demonstrate the different levels at which the ZEB1, 
2/E-cadherin, Vimentin axis can be manipulated in vitro. As seen with these studies, 
lncRNAs can have a spectrum of different mechanisms and targets, and therefore, in-
depth analysis of their function on different pathways is essential. 
 
Wnt/β-catenin signaling 
The Wnt/β-catenin signaling pathway is another critical mediator of EMT that can 
be regulated by lncRNAs. PlncRNA-1 targets β-catenin through a competitive 
endogenous RNA mechanism with miR-204 to mediate EMT.77 In contrast, H19 and 
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TUG1 target β-catenin indirectly by targeting molecules that interact with β-catenin.66,78-
80 H19 targets PGRN and TUG1 targets KIAA1199, through miR-29b binding and miR-
600 binding respectively. As previously mentioned, H19 also mediates an effect in the 
ZEB1, 2/ E-cadherin, Vimentin signaling pathway, suggesting that lncRNAs can act on 
multiple signaling pathways through a competitive endogenous RNA mechanism.  
In contrast, CYTOR activates the Wnt/β-catenin signaling pathway by blocking 
casein kinase 1-mediated β-catenin phosphorylation.81 Many of the previous studies 
demonstrate lncRNAs that bind miRNA in order to mediate their effect, however the 
activity of CYTOR is distinct from this mechanism. Similarly, SLC04A1-AS1 stabilizes 
β-catenin by preventing β-catenin phosphorylation by glycogen synthase kinase-3, which 
leads to a mesenchymal phenotype.82 Both lncTCF7 and CTD903 have been shown to 
mediate EMT through Wnt/β-catenin signaling, but further work is required to delineate 
the exact mechanism of action.83,84 
 
Chromatin Remodeling and epigenetic modulation 
In recent years, epigenetic modification of gene expression through chromatin 
remodeling via histone acetylation and methylation has been shown to be a major 
mediator of EMT. XIST, MALAT1, and HOXD-AS1 mediate EMT, in part, through 
regulation of EZH2.85-88 EZH2 is the enzymatic component of the polycomb repressive 
complex 2, which is critical in histone methylation. All three of these lncRNAs mediate 
this effect through a competitive endogenous RNA mechanism, by binding different 
miRNAs, and are associated with adverse clinical outcomes.63,86,87 Interestingly, 
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MALAT1 is increased in expression in chemoresistant cell lines compared to parental 
cells, and is associated with reduced recurrence-free survival.87 Modulation of MALAT1 
may then be a target for patients with poor chemotherapy response. Similarly, HIF1A-
AS2 directly binds miR-129, which in turn regulates DNA methylation through 
DNMT3A, mediating EMT. DNMT3A is an enzyme that transfers methyl groups to CpG 
islands leading to gene repression.89 
In contrast to these mechanisms, both TUG1 and SATB2-AS1 regulate EMT 
through histone acetylation.78,90 The signaling mechanism for SATB2-AS1 is complex, 
whereby SATB2-AS1 acts through a scaffold mechanism to recruit p300 and to acetylate 
H3K27 and H3K9 at the promoter region of SATB2. This leads to the subsequent 
recruitment of HDAC1 to the promoter of SNAIL by SATB2, thereby silencing SNAIL 
and inhibiting epithelial-mesenchymal transition. The mechanism through which TUG1 
mediates its effect requires further investigation as it is has not been fully explored.78  
 
JAK-STAT3 signaling  
Both BC200 and lncRNA AB073614 act through a transcriptional factor 
mechanism to reduce STAT3 phosphorylation in the JAK/STAT signaling cascade.91,92 







The mTOR pathway is a complex signaling family involved in EMT. Both 
ZFAS1 and UCA1 induce EMT through a competitive endogenous RNA mechanism but 
target different molecules in the pathway.93,94 Through binding with miR-150, ZFAS1 
targets VEGFA and subsequently Akt in the mTOR signaling pathway. Few studies 
examine upstream regulators of lncRNA and interestingly, the authors demonstrate an 
upstream regulator of ZFAS1 through the SP1 transcription factor.93  UCA1 directly 
binds miR-143, which targets mTOR to induce EMT. In addition, Jahangiri et al. 
demonstrated the complexity of the tumor microenvironment and its effect on lncRNA 
expression by co-culturing the cells with cancer-associated fibroblast-conditioned 




As previously mentioned, H19 acts through a competitive endogenous RNA 
mechanism in both Wnt/β-catenin signaling and in ZEB1, 2/ E-cadherin, and Vimentin 
signaling. In addition, H19 also directly binds miR-194, which targets FoxM1.95 FoxM1 
is a downstream target in the MAPK/ERK signaling pathway. This suggests that H19 
mediates EMT, in part, through a number of different signaling pathways by targeting 
different miRNAs. This may suggest its potential use as a therapeutic target. SNHG7 also 
affects the MAPK/ERK signaling pathway through a similar mechanism by targeting 
 29 
 
GALNT1 through binding miR-216b in a competitive endogenous RNA mechanism.96 
GALNT1 is also a downstream molecule in the MAPK/ERK signaling pathway.97  
Three other lncRNAs identified in the search were hypothesized to mediate their 
effect on EMT through MAPK/ERK signaling. Both BANCR and NNT-AS1 have 




The TGF-β signaling superfamily is a complex mediator of EMT. Both PVT1 and 
LINC001133 mediate EMT through TGF-β signaling.101,102 Takahasi et al. used a 
bioinformatics approach to identify pathways enriched by PVT1 knockdown.101 
LINC001133 has a complex role in TGF-β signaling in that it directly binds SRSF-6, an 
alternative splicing factor, to mediate EMT. However, SRSF-6 was found to mediate 
EMT, independent of LINC001133 expression. 
 
Other signaling pathways: 
A number of other studies describe lncRNAs that target different signaling 
pathways in order to mediate EMT.  
As previously mentioned XIST mediates signaling through the ZEB1, 2/E-
cadherin, Vimentin pathway and through chromatin remodeling. However, it also targets 
Neuropilin 2 signaling through a competitive endogenous RNA mechanism with miR-
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486.103 This study is limited in that it does not explore downstream targets of NRP2 
marking it as a potential area of future research as NRP2 is involved in a number of 
signaling pathways.104 The study does, however, demonstrate how modulating a single 
lncRNA may have multiple effects on different signaling pathways, which suggests that 
in-depth investigation of a lncRNA is justified to identify its full role. 
CRCMSL also functions through a competitive endogenous RNA -like 
mechanism, but it binds HMGB2 in the cellular cytoplasm and prevents its shuttling to 
the nucleus. In turn, this prevents the interaction between HMGB2 and OCT4 in the 
nucleus, promoting a mesenchymal phenotype.105 This is a different mechanism to the 
other included studies that demonstrate that lncRNAs bind miRNAs, and shows the 
complexity in studying lncRNAs.  
Both lncRNA-ATB and LINC00959 mediate an effect on EMT through caspase 
signaling, but lncRNA-ATB is increased in colon cancer, whereas LINC00959 is 
decreased in colon cancer compared to normal tissue.106 83 Further work is needed to 
identify the exact method through which both of these lncRNAs mediate their effects in 
EMT, since caspase signaling is typically associated with apoptosis. FOXD2-AS1 is able 
to mediate EMT through NOTCH signaling, but the exact mechanism requires further 
investigation.107 As previously mentioned, CYTOR can mediate EMT through 
transcriptional regulation of casein kinase 1 in the Wnt/β-catenin signaling pathway, but 
it also acts through a scaffold mechanism by mediating the interaction between NCL and 
Sam86 in the NF-κB signaling pathway.108 Unlike CYTOR, CPS1-IT1 is decreased in 
colon cancer but also acts through a transcriptional factor mechanism.109 CPS1-IT1 
induces HIF1-α signaling to mediate EMT, but as those authors note, the hypoxia 
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induction model they use likely affects a number of pathways. Since the tumor 
microenvironment is a hypoxic environment, this CPS1-IT1 may represent a significant 
mediator of EMT.110 Many investigators focus on a single mechanism of action of a 
lncRNA, but they may have multiple concurrent mechanisms acting on different 
signaling cascades, which highlights the complexity of studying lncRNAs in vitro. 
These studies highlight a large number of lncRNAs that are differentially expressed 
between colon adenocarcinoma and normal colon epithelium that have a role in colorectal 
cancer carcinogenesis, and specifically in the regulation of EMT. A significant number of 
the above studies examine lncRNAs in the context of a competitive endogenous RNA 
mechanism. As lncRNA have a major role in EMT, this dissertation aims to identify 
differentially expressed lncRNAs between colon adenocarcinoma and normal colon 




















ANALYSIS OF AN RNA-SEQUENCING DATABASE TO IDENTIFY 
DIFFERENTIALLY EXPRESSED LONG NON-CODING RNAS 
 
a)  Introduction: 
As a significant proportion of the human genome is not translated into protein, 
there are a large number of potential targets for investigation. In particular, for some 
lncRNAs, expression can differ between different cancer types. There is therefore, a need 
to characterize the lncRNA expression profile for a specific cancer subtype.111 Some 
investigators have shown that lncRNAs can have paradoxical effects in different cancers, 
which further underscores the reason for investigation in a particular cancer subtype.111  
  The identification of differentially expressed lncRNA between colon 
adenocarcinoma and normal colon epithelium is important, as this may demonstrate 
lncRNAs that may be important in colon cancer carcinogenesis. 
 The competitive endogenous RNA hypothesis was initially proposed in 2011 by 
Salmena et al.112 It was proposed that RNAs could indirectly regulate the expression of 
other RNAs, through binding of miRNAs. For example, consider the case where 
“miRNA X” binds both “RNA Y” and “RNA Z”. If there is increased expression of 
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“RNA Y”, in a pathological case such as in cancer, there is relatively less “miRNA X” 
available to bind “RNA Z”, therefore allowing its expression. This is particularly true in 
the case of lncRNAs, which have a well-defined function of acting in a competitive 
endogenous RNA mechanism, or miRNA sponge mechanism. 
The aim of this portion of my work was to identify a number of lncRNAs that are 
differentially expressed between colon adenocarcinoma and normal colon epithelium 
using an RNA-sequencing data set. We hypothesized that these lncRNAs would have an 
interaction with target miRNAs that in turn could be identified using a bioinformatics 
tool.  
 
b) Results:  
1) The Cancer Genome Atlas 
The Cancer Genome Atlas is a program from the National Institutes of Health in 
the United States. The aim of this program was to collect patient clinical and sequencing 
data. At present the program has approximately 10,000 patients enrolled, with over 50 
cancer types represented. The colorectal adenocarcinoma program was initially published 
in 2012 with approximately 300 patients.113 Since then, the program has expanded to 
approximately 700 patients. Although this program included both colon and rectal 
adenocarcinoma patients from NIH accredited cancer centers, none of the rectal 
adenocarcinoma patients received neoadjuvant chemoradiotherapy, which is a common 
clinical practice per the National Comprehensive Cancer Network Guidelines.9 These 




2) RNA sequencing data download and processing 
An application was made to the National Institute of Health Data Access 
Committee to obtain access to the raw sequencing data for the colon adenocarcinoma 
program. Patients with colon adenocarcinoma were identified from the Genomic Data 
Commons portal (https://portal.gdc.cancer.gov/).  The raw sequencing data set was 
downloaded on February 21st 2018 to the University of Louisville computer cluster, 
where it was encrypted until further use. 
Dr. Theodore Kalbflesich performed the data download and aligned the raw 
sequencing data to the most up-to-date human genome, using the ENSEMBL gene 
identifying codes (https://useast.ensembl.org/index.html).  
 
3)  Clinical data set download 
The associated clinical data set was downloaded using FirebrowseR 
(https://github.com/mariodeng/FirebrowseR). This data set was cross-verified using 
cBioPortal for Cancer (https://www.cbioportal.org/).114,115 Patient demographics 
included; age at diagnosis, gender, race, and body mass index (BMI). Cancer specific 
details included; American Joint Commission on Cancer stage116, microsatellite 
instability status, lymphatic invasion, venous invasion, and preoperative serum 





4)  Differential Gene Expression between paired colon adenocarcinoma and normal 
colon epithelium 
 Using the clinical data as a means of identifying appropriate patients for 
comparison, we identified 40 patients with colon adenocarcinoma who also had an RNA-
sequencing data file for adjacent normal colon epithelium. The baseline demographic 
data of these 40 patients are described in Table 2. Dr. Sudhir Srivastava performed a 
differential gene expression comparison between the paired colon adenocarcinoma and 
normal colon epithelium data. There was a distinct differential clustering of the colon 
adenocarcinoma samples compared to the normal colon epithelium samples, as 
demonstrated by a multidimensional scaling plot (Figure 10).  
The pipeline for identifying a number of differentially expressed lncRNAs is 
described in Figure 11. Some 33,514 transcripts were identified from a comparative 
analysis of all transcripts, of which 9,853 were non-coding. Using the cut-offs of a log 
fold change of greater than 1.5 or less than 1.5, and a false discovery rate of 0.05, we 
identified 348 differentially expressed non-coding RNAs. Of these non-coding RNAs, 
120 were increased in expression in cancer compared to normal epithelium, and 228 were 






5) Validation of differentially expressed non-coding RNAs in the colon adenocarcinoma 
cohort 
The expression values of 70 of the most differentially expressed lncRNAs, along 
with 10 housekeeper genes, were confirmed using all of the available colon 
adenocarcinoma patients from The Cancer Genome Atlas. A similar differential gene 
expression analysis was performed by Dr. Sudhir Srivastava to confirm that these genes 
remained significantly differentially expressed when the sample size was increased. 
 
6) Selection of candidate molecules- manually curated for criteria 
From these two comparative analyses, a number of selection criteria were used to 
identify candidate lncRNAs for further investigation. All of the lncRNAs were confirmed 
to be increased in expression in colon adenocarcinoma compared to normal colon 
epithelium. In addition, because a large number of non-coding RNAs may not have an in 
vitro effect, we sought to investigate lncRNAs which have been described to have a 
cellular function in the literature, through a PubMed and EMBASE search.  
Each lncRNA was entered to the bioinformatics prediction program DIANA-
lncBASE v2.0.117 This is a bioinformatics tool that allows for the identification of both 
predicted and experimentally validated lncRNA-miRNA direct binding interactions. The 
ENSEMBL gene ID of each lncRNA was entered into the program and the 




Table 2. Demographics and tumor details of colon adenocarcinoma patients with both a 



















Height (cm)(median, IQR) 169 (161-180) 
Weight (kg) (median, IQR) 74 (63-95) 
Body Mass Index (kg/m
2
) (median, IQR) 
26.2 (23.3-32.1) 
Pre-operative CEA (ng/mL)  (median, IQR) 4.3 (1.6-18.4) 
Tumor location                                















Tumor Stage                                    











Microsatellite Instable- Low 
Microsatellite Instable- High 






Lymphatic Invasion                                
 Yes 
No 





Venous Invasion                                      
 Yes 
No 










Figure 10. Multidimensional Scaling plot demonstrating differential clustering of colon adenocarcinoma samples compared to normal 







Figure 11. Schematic of candidate lncRNAs identified from exploratory differential gene expression analysis between colon 




Finally, the expression of these lncRNAs was verified to be present in colon 
adenocarcinoma cell lines by using the Cancer Cell Line Encyclopedia.118 This resource 
from the Broad Institute and the Massachusetts Institute of Technology, has RNA-
sequencing data on over 1000 cell lines and allows investigators to ensure that a given 
cell line expressed a certain RNA. This allowed us to select three colon adenocarcinoma 
cell lines with robust expression of the lncRNAs. This selection process yielded seven 
candidate lncRNAs for further investigation (Table 3).  
Following our initial comparative analysis, six of the seven lncRNAs had 
persistently increased expression in colon adenocarcinoma compared to normal colon 
epithelium. FAM83H-AS1 expression data was not available on Firebrowse. The Cancer 
Cell Line Encyclopedia was used to compare the expression of each of the lncRNAs in 
each cell line. ZFAS1 and GAS5 had the most consistent and robust expression across 
our three cell lines, SW480 (Stage II/ Duke’s B colon adenocarcinoma), HT29 (Stage III/ 
Duke’s C colon adenocarcinoma), and Caco2 (Stage unknown/ Duke’s stage unknown), 
but there was heterogeneity of expression among the others. H19, PVT1, and GAS5 were 
the most commonly investigated lncRNAs, yielding the highest number of papers 
investigating the lncRNA from our literature search. There were 20 miRNA confirmed 
targets of PVT1, 33 miRNA targets for UCA1, 28 miRNA targets for H19, 5 miRNA 
targets of FER1L4, 18 miRNA targets for GAS5, and 5 miRNA targets for ZFAS1. There 
were no confirmed miRNA targets for the lncRNA FAM83H-AS1. The interactions for 
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2.42 1.37E-41 Not available -0.09 4.12 3.42 10 0 0 48 
PVT1 2.37 2.99E-41 7.70 1.68 3.49 0.87 1129 41 20 21 
UCA1 2.30 3.54E-10 7.54 1.35 1.50 5.61 198 53 33 2 
H19 2.05 1.11E-7 4.14 -1.81 -0.79 2.45 2467 198 28 172 
FER1L4 2.89 1.89E-14 6.15 -3.56 4.95 -1.78 122 4 5 5 
GAS5 1.14 4.02E-14 2.29 6.96 6.71 6.34 233 39 18 199 
ZFAS1 1.51 6.87E-24 3.20 8.12 6.85 8.06 50 10 5 162 
FPKM- Fragments Per Kilobase of transcript per Million mapped reads, N/A- Not available 
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Figure 12. Confirmed miRNA that target each of the 7 selected lncRNA, identified 
through both bioinformatics prediction and literature reporting positive lncRNA-miRNA 
direct binding, a) PVT1 Targets, b) UCA1 targets, c) H19 targets, d) FER1L4 targets, e) 




Modified from DIANA lncBASE  v2.  Paraskevopoulou MD, Vlachos IS, Karagkouni D, 
Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-LncBase v2: indexing microRNA 











































This chapter describes a path to discover a number of differentially expressed 
RNAs and lncRNAs from an RNA-sequencing data set. By comparing patients with both 
a colon adenocarcinoma and a normal adjacent colon epithelium RNA-sequencing data 
file, we identified a large number of differentially expressed RNAs. After confirmation of 
differential expression in the entire cohort of patients with colon adenocarcinoma 
(N=441), we selected seven lncRNAs for further investigation on the basis of a number 
of criteria. 
By integrating The Cancer Genome Atlas and the Cancer Cell Line Encyclopedia, 
it allows investigators to select differentially expressed RNA in clinical samples and to 
select appropriate cell lines for investigation on the basis of their target lncRNA and other 
RNA expression. Historically non-coding RNAs were thought to not have a function, but 
through different bioinformatics approaches they are now recognized to have a major 
function in normal cellular signaling and in cancer signaling.119  
We have identified a number of experimentally verified miRNA targets for each 
lncRNA with the exception of FAM83H-AS1. These interactions are from both high-
throughput sequencing interactions and with luciferase reporter assay-based techniques. 
Interestingly, the miR-200 family appears to target ZFAS1, H19, and PVT1, which is a 
major regulator of epithelial-mesenchymal transition in cancer.40 In addition, both GAS5 
and PVT1 directly target miR-203 which is another regulator of epithelial-mesenchymal 
transition in cancer.120  
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 A number of investigators combine colon adenocarcinoma and rectal 
adenocarcinoma together when using The Cancer Genome Atlas, but there are significant 
molecular and clinical differences between these two types of large bowel cancer.  Right- 
sided colon adenocarcinomas are more likely to be high microsatellite instable tumors, 
whereas left-sided colon adenocarcinomas are more likely to be chromosomal instable 
tumors. 20  BRAF mutations more commonly occur in colon adenocarcinomas, and rectal 
adenocarcinomas typically have APC and TP53 mutations. 21 Clinically, rectal cancer has 
a tendency towards pulmonary metastases, whereas colon cancer tends to develop liver 
metastases. 121,122 Typical adjuvant chemotherapy strategies for colon cancer include 
fluorouracil-based therapies.22,123 Finally, as previously mentioned, none of the patients 
in the rectal adenocarcinoma cohort received preoperative neoadjuvant 
chemoradiotherapy, a current standard of care for locally advanced cancers.113 We 
therefore restricted our use of The Cancer Genome Atlas to patients with colon 
adenocarcinoma.  
In the previous chapter, we described a large number of lncRNAs that are 
differentially expressed in colon adenocarcinoma compared to normal colon epithelium 
and that have a role in EMT from the literature. Using a methodical approach to identify 
highly differentially expressed lncRNAs between colon adenocarcinoma and normal 
colon epithelium, we selected seven lncRNAs with experimentally validated miRNA 










HYPOTHESIS, SPECIFIC AIMS, AND EXPERIMENTAL PLAN 
 
a)  Key Objective 
To identify differentially expressed lncRNAs in colon adenocarcinoma compared 
to normal adjacent colon epithelium from an exploratory RNA-sequencing analysis, and 
to validate their expression in clinical samples.  To furthermore characterize the 
mechanism of action and phenotypic function of selected lncRNAs in colon 
adenocarcinoma cell lines.  
 
b)  Hypothesis 
We hypothesize that ZFAS1, a lncRNA identified from an exploratory 
comparative RNA-sequencing analysis, can modulate the behavior of three colon cancer 
cell lines in vitro.   
The interrogation of RNA-sequencing data sets allows a transcriptome-wide 
analysis of RNAs between colon adenocarcinoma samples and normal colon epithelium. 
Using these data, differentially expressed lncRNAs can be identified for investigation in 
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colon adenocarcinoma cell lines. ZFAS1 is a well-characterized lncRNA that has been 
shown to promote tumor progression in different cancers. However, its role in colorectal 
cancer has not been fully elucidated specifically regarding its mechanism or effect on 
colon cancer cell line phenotype.  
 
c)  Specific Aims 
1) To validate the expression of differentially expressed lncRNAs identified from 
a RNA-seq comparison between paired colon adenocarcinoma and normal adjacent colon 
epithelium, in clinical samples from the University of Louisville tissue biorepository. 
2) To investigate the effect of lncRNA ZFAS1 knockdown on target miRNA 
expression as well as the effect of transfection with miRNA mimics on lncRNA 
expression. 
3) To demonstrate the effect of lncRNA knockdown on colon cancer cell line 
phenotype, specifically focusing on ZFAS1 and the signaling pathway through which it 
mediates EMT.   
 
d)  Experimental Plan 
The overall goal of this project is to identify differentially expressed lncRNAs in 
an RNA-seq database, and then to investigate how the selected lncRNAs modulate colon 
cancer cell line behavior in vitro. We will in turn validate the results of the RNA-
sequencing data set in patient samples from the University of Louisville tissue 
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biorepository. The effect of lncRNA knockdown on target miRNAs will be examined 
with a specific focus on ZFAS1. To further define this, miRNA mimics will be 
transfected to investigate for a reciprocal change in lncRNA expression. This will direct 
further investigation into a target signaling pathway and into the role of the lncRNA on 
cellular phenotype. The role of ZFAS1 on the EMT signaling cascade, the ZEB1/ E-
cadherin, Vimentin signaling pathway will be examined in detail as shown in Figure 13. 

























Figure 13. Hypothesis overview- The lncRNA ZFAS1 which was identified to be differentially expressed from the exploratory RNA-

















MATERIAL AND METHODS 
 
a.  Ethics Statement: 
The experiments in this study were approved by the institutional review board at 
the University of Louisville. (IRB: 97.0361) 
 
b. The Cancer Genome Atlas: 
 
1. RNA-sequencing data 
The Cancer Genome Atlas is a program from the National Institutes of Health, 
which contains clinical and sequencing data for over 10,000 patients from 68 different 
primary sites. There are different tiers of access to the data. An application to obtain 
access to the restricted tier of raw sequencing data was made to the National Center for 
Biotechnology Information, which contains the original sequencing data files. This 
application was made and approved through 
https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login. The sequence data for patients 
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with colon adenocarcinoma were downloaded to the University of Louisville computer 
cluster and stored with an encryption to the standard of the National Institutes of Health. 
 
2.  RNA-sequencing data alignment and statistical analysis 
The data for all patients was aligned by Dr. Theodore Kalbfleisch using STAR 
(Spliced Transcripts alignment to a Reference). This analyzed data was annotated to the 
known ENSEMBL identifier codes (https://www.ensembl.org/index.html). For an initial 
comparative analysis, all patients with both a colon adenocarcinoma RNA-seq data file 
and a normal adjacent colon epithelium RNA-seq data file were selected. A comparative 
analysis of these patients was conducted by Sudhir Srivastava, using a binomial 
regression model, to provide a fold change and adjusted p-value (false discovery rate) for 
each gene.  
The normalized gene expression for ZFAS1, its target microRNAs, and target 
messenger RNAs were downloaded using cBioPortal for Cancer Genomics 
(https://www.cbioportal.org/).115,124 The expression format of ZFAS1 and its target 
mRNAs was in the format of RSEM (Reads Per Kilobase Per Million Mapped Reads).125 
The format of the miRNA data is in RPM (Reads Per Million miRNA Precursor Reads). 






3.  Clinical data set 
The clinical data set for the colon adenocarcinoma patients from The Cancer 
Genome Atlas was downloaded using FirebrowseR 
(https://github.com/mariodeng/FirebrowseR) and using R Studio (Rstudio Inc, Boston 
MA). The validity of the clinical data was verified by downloading the clinical data from 
cBioPortal for Cancer Genomics (https://www.cbioportal.org/).  
 
c. Human Samples: 
  1. Human Whole Tissue RNA Extraction 
Prior to and during the process of RNA extraction, RNase Zap (Ambion, USA) 
was used on workspace surfaces and tools to prevent tissue RNA degradation.  The 
Qiagen miRNeasy® extraction kit (Qiagen, Hilden, Germany) and protocol were used for 
extraction. Six tubes from the kit were labeled with a sample identifier: four 1.5 mL 
tubes, one Qiashredder column (Qiagen, Hilden, Germany), and one micro filter column. 
A container of ice was used to maintain low temperatures while working with fresh 
tissue. Plastic petri dishes were cleaned with 70% ethanol and sprayed with RNase Zap 
before use. A scale was used to measure the mass of the tissue cut. 
The tissue of interest was taken from the freezer, placed on ice, then cut and its 
mass recorded. Once all the tissue was cut, it was minced with a sterile scalpel into a gel 
consistency. The desired tissue mass was between 15-30 mg. The minced tissue was then 
placed into a tube with 700 μL of QIAzol lysis reagent (QIAGEN, miRNeasy kit, Hilden, 
Germany) and incubated for 5 minutes at room temperature. The homogenate was added 
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to the shredder column and centrifuged for 2 minutes at 17,000 x g. The shredder was 
removed from the collection tube and placed in a 1.5mL tube containing 140 μL of 
chloroform. The tube was vortexed for 15 seconds before being centrifuged at 12,000 x g 
for 15 minutes. The top layer of the aqueous solution was extracted, without disturbing 
the interface between the top and bottom layers. A volume of 100% ethanol was mixed 
with this extracted layer, equaling one and a half times the volume of the extracted layer. 
700 μL of the sample was pipetted into a QIAgen filter column and centrifuged at 
8,000 x g for 15 seconds, after which the effluent was discarded. The filter column then 
underwent a series of washes using propriety solutions within the kit beginning with 700 
μL of RWT solution followed by 500 μL of RPE solution. Both washes occurred at 8,000 
x g for 15 seconds, with the effluent being discarded.  Another 500 μL of RPE solution 
was added and centrifuged at 8,000 x g for 2 minutes. The filter column was then 
transferred into a new 1.5 mL collection tube, and 30 μL of RNase-free water (QIAGEN 
miRNeasy kit, Hilden, Germany) was pipetted directly onto the filter. The tube was then 
centrifuged for 1 minute at 8,000 x g to elute the miRNA.  Samples were stored at -80C. 
 
2. Human Whole Tissue Protein Extraction 
Frozen whole colon adenocarcinoma tissue and matched normal adjacent tissue 
samples were obtained from the University of Louisville Surgical Biorepository. Normal 
adjacent tissue was excised 10 cm away from the tumor site. Macrodissection of the 
tissue produced 20 to 50 mg pieces -which were used for protein extraction using 
hematoxylin and eosin stained slides as a guide. Tissue was homogenized on ice using a 
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Tissue Tearor (Biospec Products, Inc., Bartlesville, OK) in 300 μL of 
radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich, St. Louis, MO) 
supplemented with 0.1% protease inhibitor and 0.1% phosphatase inhibitor (Thermo 
Fisher Scientific, Waltham, MA). Tissue samples were sonicated with a Sonifier 250 
(Branson Ultrasonics, Danbury, CT) and transferred into 1.5 mL microcentrifuge tubes. 
The tubes were then centrifuged at 11,000g for 10 minutes. Pelleted debris was discarded, 
and the supernatant extracted and stored at -80°C until needed. Total protein 
concentrations were quantified using a bicinchoninic acid (BCA) protein quantification 
assay (Thermo Fisher Scientific, Waltham, MA). Samples were measured in duplicate. 
BCA assay plates were read on a SPECTRAmax PLUS spectrophotometer (Molecular 
Devices, San Jose, CA) at 540 nm.  
 
d.  Laser Capture Microdissection: 
1. Human Tissue Acquisition and Sectioning  
Fresh frozen samples of malignant colon adenocarcinoma and normal adjacent 
colon epithelium from 24 patients were obtained from the University of Louisville 
Surgical Biorepository. The normal tissue sample was taken 10cm from the tumor site.  
Tissue sections from these samples were cut at 7µm thickness and mounted on negatively 
charged slides from the Histogene™ LCM Frozen Section Staining Kit (Thermo Fisher 
Scientific, Waltham, MA) by the University of Louisville, Department of Pathology.  
One slide per tissue sample was stained using hematoxylin and eosin for reference. Other 




2. Staining of Fresh Tissue Sections 
The protocol from Applied Biosystems Arcturus Staining Kit (Thermo Fisher 
Scientific, Bedford, MA) was followed. One slide at a time was stained and dehydrated 
for each Laser Capture Microdissection session. The protocol was implemented using 
seven plastic Coplin tubes, prefilled with dehydrating solutions: 25 mL 75% ethanol 
(tube #1 & 4), 25 mL distilled water (tubes #2 & 3), 25 mL 95% ethanol (tube #5), 25 mL 
100% ethanol (tube #6), 25 mL xylene (tube #7). Each slide was dipped into tubes 1-2 
sequentially for 30 seconds, then placed flat on an RNase free surface and stained with 
Histogene™ staining solution for 20 seconds. The stain was drained from the slide using 
a Kimwipe (VWR, Radnor, PA) and then placed into tubes 3-6 sequentially for 30 
seconds each and into tube 7 for 5 minutes. The slide was then placed horizontally on an 
RNase free surface and air dried for 5 minutes. 
 
3.. Laser Capture Microdissection 
Immediately following slide staining, normal epithelium or tumor tissue was 
identified by light microscopy at 4x and 10x magnification using the H&E slide as a 
reference. Tissue of interest from the stained slide was then laser captured at 10x 
magnification onto CapSure Macro LCM Caps (Thermo Fisher Scientific, Waltham, 
MA) using the ArcturusXT™ Laser Capture Microdissection System. After laser capture, 
caps were placed onto a microcentrifuge tube, containing 50μL of extraction buffer from 
the PicoPure™ RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA) and 
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inverted so that the buffer came into contact with the tissue on the cap. The tubes were 
then incubated at 42C for 30 minutes. After incubation the tubes were centrifuged at 800 
x g for 2 minutes and stored at -80C. 
 
4. RNA extraction 
Isolation of total RNA was performed using the Arcturus PicoPure™ RNA 
Isolation Kit (Thermo Fisher Scientific, Baltics UAB) and protocol. Microcentrifuge 
tubes with cell extract from the LCM were thawed. 70% ethanol was added to each 
centrifuge tube so that the cell extract to 70% ethanol ratio was 1:1. RNA purification 
columns were pre-conditioned with 250 μL conditioning buffer, incubated for 5 minutes 
at room temperature, and centrifuged in the provided collections tubes at 16,000 x g for 1 
minute. After conditioning, 100 μL cell extract and ethanol mix were pipetted into the 
RNA purification column. The columns were centrifuged for 2 minutes at 100 x g, and 
then at 16,000 x g for 30 seconds. Effluent was removed from the collection tube. The 
tube then underwent a series of washes using 100 μL of wash buffer 1, followed by 100 
μL of wash buffer 2. Both washes were centrifuged for 1 minute at 8,000 x g. Effluent 
was discarded between each spin. The purification column was transferred to a new 0.5 
mL microcentrifuge tube, and 20 μL elution buffer was pipetted directly onto the 
membrane of the column. The tube was incubated 1 minute at room temperature and 
centrifuged 1 minute at 1,000 x g, followed by 1-minute centrifugation at 16,000 x g to 




e.  Cell lines: 
The Cancer Cell Line Encyclopedia (https://portals.broadinstitute.org/ccle) is a 
Broad Institute (Boston, MA) database that contains RNA-seq expression data from 
common cancer cell lines. This facilitates selection of cell lines expressing RNAs of 
interest. After consulting this database, the HT-29 (ATCC® HTB-38™; Stage III), SW-
480 (ATCC® CCL-228™; Stage II), and Caco2 (ATCC® HTB-37™; Stage unknown) 
colon adenocarcinoma cell lines were purchased from the American Type Culture 
Collection (Manassas, VA). The morphology of each cell line as examined by light 
microscopy is shown in Figure 14-16. Gene mutations and the consensus molecular 
subtype of each cell line are described in Table 4.126 
i. HT-29 (ATCC® HTB-38™)  
 The HT-29 cell line is derived from a 44-year-old woman with a stage III (Duke’s 
C) colon adenocarcinoma. As per the guidelines from American Type Culture Collection 
(ATCC), these cells were grown in McCoy’s 5A medium, supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin, streptomycin, amphotericin B, and 1% L-glutamine. 
HT-29 cells have a more epithelial phenotype and are more locally proliferative than 
invasive. 
ii. SW-480 (ATCC® CCL-228™)  
The SW-480 cell line is derived from a 50-year-old man with a stage II (Duke’s 
B) colon adenocarcinoma. The SW-480 cell line was maintained in RPMI-1640 medium, 
supplemented with 10% FBS, 1% penicillin, streptomycin, amphotericin B, and 1% L-
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glutamine, as per ATCC guidelines. SW-480 cells have a mesenchymal phenotype and 
have a more invasive phenotype rather than a locally proliferative phenotype. 
iii. Caco2 (ATCC® HTB-37™) 
The Caco-2 cell line cells were grown in Eagle's Minimum Essential Medium 
(EMEM), supplemented with 10% FBS, 1% penicillin, streptomycin, amphotericin B, 
and 1% L-glutamine, as per ATCC recommendations. Caco-2 cells have a mesenchymal 
phenotype, and have a more invasive phenotype with slow proliferation. 
All cell lines were cultured in 75cm3 or 125cm3 cell culture flasks (Corning Inc., 
Corning, NY) and incubated at 37°C and 5% CO2. Cell lines were authenticated using 
Short Tandem Repeat profiling (ATCC Cell Line Authentication service, Manassas VA). 











Figure 14. Morphology of the HT-29 cell line (Stage III) as examined with light 
microscopy at low and high density viewing. 
 
At low confluency, the HT-29 cells grow individually and appear rounded. At 








Figure 15. Morphology of the SW-480 cell line (Stage II) as examined with light 
microscopy at low and high-density viewing. 
 
At low cell density the SW-480 cell line grows in singular rounded cells, but at a 
higher confluency, the SW480 cells take on a more polygonal shape. The cells may also 
take on a tethered appearance at higher confluency. 
 
 




Figure 16. Morphology of the Caco-2 cell line (Unknown Stage) as examined with light 
microscopy at low and high density viewing. 
 
At low cell density the Caco-2 cells have a heterogeneous appearance in that the 
cells grow as single cells or in clumps, but also can have variation in individual cell size.  
At a higher confluency, the Caco-2 cells grow with a sheet-like appearance and can 








Table 4. Gene mutations and molecular characteristics of the 3 cell lines used for 
in vitro studies.126 
Cell line 
Gene Mutations Molecular Characteristics 














p.G12V wt wt wt MSS CIMP- 4 
Caco-2 (Stage 
unknown) 
p.E204X wt wt wt wt MSS CIMP- 4 
TP53- Tumor Protein 53 gene, KRAS- Kirstin Rat Sarcoma gene, BRAF- B 
rapidly accelerated fibrosarcoma gene, PIK3CA- Phosphatidylinositol 3-kinase gene, 
PTEN- Phosphatase and tensin homolog gene, CIMP- CpG island methylator phenotype, 









f.  Small interfering RNA (siRNA) 
Five small interfering RNAs (siRNA) were purchased from DharmaconTM 
(Horizon Inspired Cell Solutions, Lafayette, CO). The LincodeTM siRNAs were as 
follows: Human GAS5 Control (Reference: D-001310-10-05), Non-targeting siRNA 
(Reference: D-001320-10-05), Human PVT1 (Reference: R-029357-00-0005), Human 
ZNFX1-AS1 (Reference: RU-034485-00-0005), and Human GAS5 (Reference: R-
188293-00-0005). Each siRNA was delivered as a dry pellet. A 5X siRNA buffer 
[DharmaconTM (Horizon Inspired Cell Solutions, Lafayette, CO)] was diluted to a 1X 
concentration with RNase free water. This 1X siRNA buffer was then used to resuspend 
siRNA pellets to 5 μM solutions as recommended by the manufacturer. Once 
resuspended, solutions were placed on an orbital shaker for 30 minutes at room 
temperature and then centrifuged. The concentration of each solution was confirmed to 
be 5 μM using a NanoDrop® 2000 spectrophotometer (ThermoFisher ScientificTM, 
Waltham, MA, USA). Resuspended siRNAs were aliquoted per the manufacturer’s 
recommended amounts and stored at -20°C. 
HT-29, SW-480, and Caco2 cells were seeded in 6-well plates at 1.66 x 105 cells 
per well and allowed to grow to confluence for 24 hours in Antibiotic/Antimycotic (A/A) 
free media. Following manufacturer’s instructions for transfection, 5 μM siRNA was 
diluted with serum-free media, and further combined with a DharmaFECT reagent (x mL 
DharmaFECT solution and x mL serum-free media). After removing the original media, 
the combined transfection reagents were added to each respective well of the 6-well plate 
and diluted with A/A free media. Transfection was subsequently performed for 24-hours 
at 37oC in 5% CO2, after which the solution in each well was removed and replaced with 
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2 mL of A/A free media. Cells were then further incubated for downstream experiments 
at variable time points depending on the experiment.  
 
g.  RNA extraction 
i. Protein and RNA Isolation SystemTM (PARIS) Kit (Life Technologies®, Carlsbad 
CA). 
Cells from culture were placed in a 15mL conical tube, and pelleted at a speed of 
113 x g or 7 minutes using an Eppendorf Centrifuge 5804 R (Eppendorf AG, Hamburg, 
Germany).  The supernatant was removed, and the cells resuspended in 1 mL cold 
Phosphate Buffer Saline (PBS). The resuspension was transferred to a 1.5 mL 
microcentrifuge tube, and pelleted at 500 x g for 1 minute using an AccuSpin Micro 17 
microcentrifuge (Fisher Scientific, Hampton, NH).  
The Protein and RNA Isolation System (PARIS) kit (Life Technologies®, 
Carlsbad CA) was used to separate the nuclear fraction of RNA from the cytoplasmic 
fraction. Samples of cells were resuspended with 300 μL ice-cold Cell Fractionation 
Buffer. The pellet was gently resuspended by carefully pipetting up and down 3-4 times 
to prevent contamination of the cytoplasmic fraction with nuclear components. Once the 
mixture was homogenized, cells were incubated on ice for 5-10 minutes.  After 
incubation, the cells were centrifuged at 500 x g for 5 minutes at 4°C in order to separate 
the mixture into nuclear (pellet) and cytoplasmic (supernatant) fractions. The supernatant 
was carefully collected, placed into a new microcentrifuge tube, and stored on ice until 
further use. The pellet was then washed with ice-cold Fractionation Buffer and 
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centrifuged at 500 x g for 1 minute at 4°C in order to ensure that there was little 
contamination between the fractions. Next, the supernatant was removed and discarded. 
The nuclear pellet was resuspended in 300 uL ice-cold Cell Disruption Buffer by 
vigorously pipetting to ensure lysis and homogenization. The nuclear fraction was then 
placed on ice until further use.   
To begin RNA Isolation, 300 μL 2X Lysis/Binding Solution was added to the 
total, nuclear and cytoplasmic fractions. Next, an equal amount of 100% ACS grade 
ethanol was added to each fraction. The samples were then pipetted into the supplied 
filter cartridges/collection tubes, and centrifuged at 15,000 x g for 1 minute. The effluent 
was discarded, and then 700 μL Wash Solution 1 added to each sample. The tubes were 
then centrifuged at 15,000 x g for 1 minute. The effluent was discarded, and 500 μL 
Wash Solution 2/3 was added. The sample was once again centrifuged at the same 
parameters as previously. This previous step is then repeated, with another 500 μL Wash 
Solution 2/3 being added to the tubes. Next, the filter cartridges were added to new tubes, 
and 30 μL Elution Solution heated to 95°C was added to each tube. Samples were then 
centrifuged at 15,000 x g for 30 seconds. Another 30 uL Elution Solution was applied to 
the filter, and samples centrifuged at 15,000 x g for 30 seconds. The filter cartridges were 
discarded, and the concentration and purity of the isolated RNA obtained using 






ii. Qiagen miRNeasy Mini Kit (Qiagen, Hilden, Germany) 
The media from one well in a 6-well plate was removed without disrupting the 
layer of cells. The cells were lysed using 700 μL Qiazol Lysis Reagent (Qiagen, Hilden, 
Germany). The solution was then stored at -80oC for further RNA processing. Total RNA 
extraction was performed using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Six 
hundred μL Chloroform (Sigma Aldrich) was added to the lysis solution, vortexed, and 
centrifuged at 12,000 x g for 15 minutes. The top, clear aqueous phase was transferred to 
a new tube and washed with 100% ethanol, followed by centrifugation at 8,000 x g for 15 
seconds. A series of washes was then completed following the manufacturer’s protocol, 
discarding the effluent after each successive wash. Total RNA was then eluted with 30 
μL nuclease-free H2O and centrifuged at 8,000 x g for 1 minute. Total RNA 
concentration and purity were assessed using Nanodrop® 2000 spectrophotometry 
(Thermo Fisher Scientific, Waltham, MA). Total RNA was considered pure and usable if 
the sample had a 260/280 ratio of 1.8-2.2. Samples were stored at -80oC until further use.  
 
h.  Reverse Transcriptase and Quantitative Real-time Polymerase Chain 
Reaction (RT qRT-PCR) 
i. Superscript™ IV VILO™ mRNA RT qRT-PCR  
For mRNA or lncRNA single assay quantification, the extracted template RNA 
was converted to cDNA using a Superscript™ IV VILO™ Master Mix with ezDNase 
enzymes (Life Technologies, Carlsbad, CA). The reverse transcription (RT) total reaction 
volume for each sample was 20μL, consisting of the following components: 
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Component Volume per 20 𝝁L reaction (𝝁L) 
Superscript™ IV VILO™ Master Mix 4.0 
Template RNA  1.0 
Nuclease Free H2O  15.0 
Total 20.0 
 
After the master mix was made, it was gently mixed with the template RNA of 
each sample in a 96-well reaction plate. The reaction plate was promptly sealed, 
vortexed, and centrifuged prior to running RT on a pre-set thermal cycler program. Upon 
completion, the cDNA was used either used immediately to perform qRT-PCR or stored 
until further use at 4oC.  
Nucleic acid quantification for RNA targets was performed using a Step-One Plus 
qRT-PCR system (Life Technologies, Carlsbad, CA). Each reaction was performed in 
duplicate at a 10μL qRT-PCR reaction volume. A master mix solution for qRT-PCR for 
each lncRNA was made as follows: 
 
Component Volume per 10 𝝁L reaction (𝝁L) 
20x TaqMan Gene expression assay 0.5 
TaqMan Fast Advanced Master Mix 5.0 
Nuclease Free H2O  3.5 
Total 9.0 
 




ZFAS1 (Hs01379985 M1)  H19 (HS00399294_g1) 
GAS5 (Hs03464472_m1)  ZEB1 (Hs01566408_m1) 
PVT1 (HS00413039_m1)  ZEB2 (Hs00207691_m1) 
FAM83H-AS1 (HS01064424_S1) CDH1 (Hs01023895_m1) 
FER1L4 (Hs00957065_g1)  Vimentin (Hs00958111_m1) 
UCA1 (Hs01909129_s1)  GAPDH (Hs02786624_g1) 
The master mix was vortexed and centrifuged to bring the solution to the bottom 
of the tube. 9 μL of each qPCR master mix was loaded into each well of a 96-well 
reaction plate, followed by 1 μL cDNA. The plate was sealed, vortexed, and centrifuged 
to bring the contents to the bottom of each well and to eliminate air bubbles. The reaction 
plate was run on a pre-set thermal cycler program using a Step-One plus qRT-PCR 
machine to determine the quantity of each of the lncRNAs in the tested samples.  
The  -ΔΔCt method was used to determine fold changes.127 The expression of 
each examined lncRNA was normalized to GAPDH, using a Ct threshold of 0.1, in order 
to calculate ∆Ct values for analysis using the comparative ∆Ct method. Analysis was 
completed for expression of each lncRNA for each CRC cell line in comparison to that of 
the non-target control lncRNA in the same CRC cell line.  
 
ii. miRNA RT qRT-PCR 
After RNA extraction, reverse transcription (RT) was performed in order to 
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measure the expression of select miRNAs. The RNA was converted to cDNA using the 
TaqMan® miRNA Reverse Transcription Kit, along with specific TaqMan® miRNA 
primers (Life Technologies, Carlsbad, CA). The specific miRNA primers consisted of the 
following: miR-200b (002251), miR-200c (002300), miR-27a (000408), miR-484 
(001821,) and miR-150 (000473). Small nuclear RNA, U6 (001973), was used as a 
housekeeper. Once cDNA was created, qRT-PCR was performed, and TaqMan® probes 
specific for each miRNA were used in order to measure their expression.  
The total reaction volume for each RT reaction was 15μL, and consisted of 7μL 
master mix, 3μL TaqMan® miRNA primer, and 5μL RNA at a concentration of 2ng/μL. 
The master mix consisted of the following:  
 
Component 
Volume per 10 𝝁L reaction (𝝁L) 
100mM dNTPs (with dTTP) 0.15 
MultiScribe™ Reverse Transcriptase, 50U/μL 1.00 
10X Reverse Transcription Buffer 1.50 
RNase Inhibitor, 20U/μL 0.19 
Nuclease-free water 4.16 
TaqMan® miRNA primer (5X) 3.00 
Total 10.00 
 
 After a master mix was created for each individual miRNA, the contents were 
vortexed and centrifuged. The tubes were then placed on ice until further use. RT was 
performed using Applied Biosystems® MicroAmp© Optical 96-Well Reaction Plate (Life 
Technologies, Carlsbad, CA). 10 μL master mix was pipetted into each well, along with 
5μL RNA. The plate was then sealed, vortexed and centrifuged. Once complete, the plate 
was then placed into an Eppendorf Mastercyler® nexus (Eppendorf, Hamburg, Germany), 
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and run at the following conditions: 16° C for 30 minutes, 42° C for 30 minutes, and 85° 
C for 5 minutes. After RT was completed, the cDNA was either stored at -20° C until 
further use or immediately used to perform qRT-PCR.  
 cDNA was quantified using Step-One Plus qRT-PCR machines (Life 
Technologies, Carlsbad, CA). Each qRT-PCR reaction was performed in duplicate, with 
a final well volume of 10μL. Similar to RT, a master mix was created for each specific 
miRNA, and contained the following:   
 
Component Volume per 10 𝝁L reaction (𝝁L) 
TaqMan® MicroRNA Assay (20X) 0.50 
TaqMan® Universal Master Mix II, no UNG 5.00 
Nuclease-free water 3.17 
Product from RT reaction (Minimum 1:15 Dilution) 1.33 
Total 10.00 
 
   
After all the components were added, the master mix was vortexed and 
centrifuged. The contents were then added to an Applied Biosystems® MicroAmp© Fast 
96-Well Reaction Plate (0.1mL) (Life Technologies, Carlsbad, CA), with each well 
receiving 8.67μL master mix followed by 1.33μL cDNA. After loading the plate, it was 
sealed, vortexed and centrifuged. The plate was then inserted into a Step-One Plus qRT-
PCR machine, and run at the following conditions for 40 cycles: 50° C for 2 minutes, 95° 
C for 10 minutes, and 60° C for 1 minute. 
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The expression of each miRNA was normalized to U6, using a Ct threshold of 1.0 
to calculate ΔCt values. Analysis was performed to determine the expression for each 
miRNA in all three transfected CRC cell lines, and compared to their expression as seen 
in untransfected samples. 
 
i.  Protein Extraction and Quantitation 
 i. Protein extraction 
A solution that consists of 1000 μL of radioimmunoprecipitation assay (RIPA) 
buffer (Sigma Aldrich, St. Louis, MO) supplemented with 2 μL protease/phosphatase 
inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA) was prepared. The media 
from each well in a 6-well plate was removed with a pipette without disturbing the cell 
layer. Cells were then lysed and harvested by removing the transfection media and adding 
150μL RIPA buffer mix to the six-well plate. A cell scraper was then utilized to collect 
the cell lysate. Samples were labeled with the date and experimental conditions. The 
samples were frozen and stored at -20°C until processing. 
Total protein was processed by sonication with a Sonifier 250 (Branson 
Ultrasonics, Danbury, CT). Each sample was sonicated 3 times with 3 pulses per 
sonication. The sonicator was cleaned between each sample with a kimwipe and 70% 
alcohol. Samples were transferred into 1.5 mL microcentrifuge tubes. The tubes were 
then centrifuged at 10,000g for 10 minutes. Pelleted debris was discarded, and the 




ii. Protein quantitation 
Total protein concentrations were quantified in a 96-well plate using a 
bicinchoninic acid (BCA) protein quantification assay (Thermo Fisher Scientific, 
Waltham, MA).  Each sample concentration was measured in duplicate at a 1:20 dilution 
with double-distilled water. For each protein sample, 38 μL water was pipetted into a 
well and 2 μL protein sample was pipetted into the well. This solution was mixed 
thoroughly and 20 μL was pipetted into the well in the row directly adjacent and to the 
right (E.g. well a3 -> well a4).  
The protein standards were made in the 96-well plate though serial dilution down 
the plate (E.g. row A -> H). This serial dilution was performed in duplicate. Forty μL 
BCA standard was pipetted into well A1 and A2. Twenty μL of double-distilled water 
was pipetted into each well in rows B to row H into both columns 1 and 2. Twenty μL 
was sequentially transferred from row A to row G with thorough mixing with each 
transfer. Row H contained only 20 μL of distilled water. Equal amounts of Pierce BCA 
Protein Assay Reagent A and B (ThermoFisher Scientific, Rockford, IL) were made into 
a solution. One hundred sixty μL of this solution was added to each well in the 96-well 
plate. The plate was covered and incubated at 37°C for 30 minutes.  
BCA assay plates were read on a SPECTRAmax PLUS spectrophotometer 
(Molecular Devices, San Jose, CA) at 540 nm. The protein concentrations were then used 
to calculate precise amounts of sample and RIPA buffer to be added to protein samples 




j.  Western Blotting 
Prior to electrophoresis, protein samples were prepared and denatured with 4X 
BoltTM LDS Sample Buffer (Life Technologies) and 2-mercaptoethanol, using a ratio of 1 
μL per 100 μL 4X Bolt. Each sample was brought to a total volume of 60 μL with RIPA 
buffer. Samples were then heated for 10 minutes at 90 C.  
Each denatured protein sample was loaded onto a BoltTM 4-12% Bis-Tris Plus gel 
(Invitrogen, Life Technologies, Carlsbad, CA) with BoltTM MES SDS Running Buffer 
(Novex, Carlsbad, CA). Each gel was run at 180V for 40 minutes. A dry transfer protocol 
on a nitrocellulose membrane was employed using iBlot Gel Transfer Stacks (Invitrogen, 
Kiryat Shmona, Israel) with an iBlot transfer system (Invitrogen, Life Technologies, 
Carlsbad, CA)  
The transfer step was set for 7 or 9 minutes depending on the protein target of 
interest. Once completed, cuts were made to the membrane to separate beta actin and 
proteins of interest. Membranes were blocked in 5% dry milk in TBST (Tris buffered 
saline Tween-20 buffer; Thermo Fisher Scientific) for 1 hour prior to being incubated 
with primary antibody for 18 hours at room temperature.  
The membranes were incubated with antibodies against E Cadherin 24E10 
(1:1000; Cell Signaling, Danvers, MA), Vimentin D21H3 XP (1:1000; Cell signaling, 
Danvers, MA), and ZEB1 sc-515797 (1:100; Santa Cruz) in 5% dry bovine serum 
albumin in TBST, and Beta actin 8H10D10 (1:5000; Cell Signaling or 1: 50,000; Cell 
Signaling) in 5% milk in TBST. Beta actin was used as a cytoplasmic and total protein 
internal control.    
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The membranes were washed with TBST 3 times following primary antibody 
incubation. Secondary HRP-conjugated anti-rabbit antibody 7074S (1:5000; Cell 
Signaling) was suspended in 5% milk. Secondary HRP-conjugated anti-mouse antibody 
7076 (1:5000; Cell Signaling) was also suspended in 5% milk. For E-cadherin and 
Vimentin detection, the anti-rabbit secondary antibody was used. For beta-actin and 
ZEB1, the anti-mouse secondary antibody was used. The blot membranes were incubated 
in the secondary antibody for 1 hour at room temperature. The membranes were washed 
in TBST again prior to imaging. The membrane was incubated in equal proportions of 
Enhanced Chemiluminescence (ECL) Reagents A and B (Bio-Rad, Hercules, CA) for 5 
minutes to detect target proteins. Immunoblots were developed and imaged using a 
ChemiDoc MP imager (Bio-Rad).  
 
k.  Functional Assays 
i. Scratch Assay 
Cells were plated at 2x106 cells per well in a 6-well plate. This concentration was 
selected to allow the cells to grow to confluence in 24 hours. The cells were maintained 
in 10% FBS supplemented media. Using a sterile 200μl pipette tip, a single vertical and 
horizontal scratch was made. The media was replaced after the scratch was made and at 
24-hour time intervals. A representative photo was taken at the time of the initial scratch, 
as well as every 24 hours up to 120 hours or until complete scratch closure. Photos were 
taken using a Nikon Eclipse TS100 microscope at 4x magnification. The average distance 
between the wound edges was calculated for each time point. These average distances 
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were used to calculate the percentage closure of the wound compared to the 0-hour time 
point. Experiments were completed with at least 3 replicates. 
 
ii. Transwell Migration 
After splitting, cells were resuspended in serum-free media (SW480: RPMI-1640 
media; HT-29: McCoy’s 5a media; Caco2: EMEM media). The cellular suspension was 
pipetted into a polycarbonate membrane insert (COSTAR Transwell Permeable Supports, 
8.0μm pore polycarbonate membrane), which was brought up to a final volume of 500 μL 
with serum-free media. SW480 cells were seeded at 2 x 105 cells/well, while HT-29 and 
Caco2 cells were seeded at 5 x 105 cells/ well. 750 μL complete media (supplemented 
with 10% fetal bovine serum) was placed in each well of a 24-well plate to serve as a 
chemoattractant. Once the chemoattractant was added, the inserts were placed into their 
respective wells. The plate was then incubated at 37°C for 24 hours. After incubation, the 
media within the insert was removed.  Non -migratory cells were removed with a cotton 
swab. Each transwell insert was stained with a Modified Giemsa staining kit (Diff-Quik 
staining kit, Electron Microscopy Sciences, Hatfield, PA). The inserts were transferred 
through 3 staining solutions, remaining in each solution for 4 minutes. Excess dye in the 
upper chamber was removed with a cotton swab. Six pictures were taken of each insert at 
10x magnification, and the migratory cells in each of these fields counted and averaged. 
Values were reported as medians (with interquartile range). Manual cell counts were 





 Cells utilized for proliferation were grown and monitored until the time of use. 
Prior to plating, cells were split and their concentration determined. HT-29, SW-480, and 
Caco2 cells were each plated at a concentration of 100,000 cells per well in 2% FBS 
supplemented media.  Cells were plated on a 12-well plate in triplicate. Cells were 
counted at the following time points: 24, 48, 72, 96 and 120 hours. At each time point, 
media was removed and 250 μL trypsin added to the designated wells at the given time 
point. Plates were then incubated for 5 minutes. After incubation, 750 μL media was 
added, and the contents of each well were thoroughly mixed. Two 10 μL samples from 
each well were then pipetted into a dual chamber cell slide (Bio-Rad Laboratories, 
Hercules, CA) and inserted into an automatic cell counter (TC20TM Bio-Rad 
Laboratories, Hercules, CA) to obtain daily cell counts. Cell counts from each replicate 
for the given time points were averaged. The average cell counts from the non-target cells 
were then compared to those of the siRNA-transfected cells. 
 Twenty μL samples from each well were pipetted into a microtube, and 20 μL of Trypan 
blue was added. This solution was mixed thoroughly with a pipette. Ten μL of the mixed 
solution was added to each of the chambers of the dual chamber cell slide (Bio-Rad 
Laboratories, Hercules, CA) and inserted into an automatic cell counter (TC20TM Bio-
Rad Laboratories, Hercules, CA) to obtain the percentage of viable cells. 
 
l.  Statistical Analysis: 
All statistical analysis was performed using SPSS v25.0 (IBM Corp, Armonk 
NY). Continuous data is reported as the median value with the inter-quartile range. 
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Categorical data is reported as the frequency and percentage. For comparisons between, 
continuous data, the independent samples t-test or Mann-Whitney U test were used, 
where appropriate.  For comparisons between categorical data, the Chi-squared test, or 
the Fischer’s exact test was used, where appropriate. All statistical tests were two-tailed 






















VALIDATION OF lncRNA EXPRESSION IN HUMAN SAMPLES AND IN 
COLON ADENOCARCINOMA CELL LINES 
 
a)  Introduction 
 
As described in the previous chapters, seven lncRNAs were identified to be 
significantly increased in colon adenocarcinoma samples compared to adjacent normal 
tissue and were selected for further study. There are, however, some issues with using 
data from The Cancer Genome Atlas. The tissue that is used for RNA-seq is from a 
macro-dissected tumor sample. Therefore it includes not only cancer cells, but also the 
stroma, with its content representing the tumor microenvironment.113 Previous studies 
have shown that the tumor microenvironment can skew data analysis by “contaminating” 
the actual tumor expression of target molecules such a miRNA.34 In addition, cells from 
within the tumor microenvironment may express or secrete lncRNAs in order to induce 
an effect on cancer cells.94 In this case, whole tissue dissection may lead to the false 
conclusion that the lncRNA is expressed from the cancer cells instead of from cells 
within the tumor microenvironment.   
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There is therefore a need to verify tissue expression in both clinical samples and in 
cell lines for in vitro mechanistic and functional analysis. We hypothesized that the 
selected lncRNAs would have an increased expression in colon adenocarcinoma 
compared to normal colon epithelium. In addition, we aimed to characterize each of the 
lncRNA, which were found to be significantly increased in the clinical samples, in terms 
of their cellular location in our colon cancer cell lines, as this may help to delineate their 
mechanism of action. For lncRNAs that are principally located in the cytoplasm, this may 




1. Expression of the seven identified lncRNAs in human samples 
Patient details from the University of Louisville biorepository are shown in table 5. 
Using laser capture Microdissection (LCM), cells were obtained from colon 
adenocarcinoma samples along with paired normal colon epithelium from the same 
patient. We then determined the difference in expression of the 7 selected lncRNA’s 
between the two tissues. All normal colon epithelium samples were taken 10cm from the 
colon carcinoma. 
Three of the seven lncRNAs, PVT1, GAS5, and ZFAS1 were significantly 
upregulated in colon adenocarcinoma samples compared to the paired normal colon 
epithelium (Fold regulation= 2.75, p=0.003, Fold regulation= 1.70, p=0.021, and Fold 
regulation=3.06, p<0.001) (Figure 17 and 18). In contrast, FAM83H-AS1 and UCA1  
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Figure 17. Differential expression of the 7 identified lncRNAs between colon 
adenocarcinoma compared to paired normal colon epithelium in laser capture 




PVT1, GAS5, and ZFAS1 (green) were significantly increased in colon 
adenocarcinoma compared to normal colon epithelium. FAM83H-AS1 and UCA1 (red) 




Figure 18. Individual differences in lncRNA expression between normal colon 
epithelium and colon adenocarcinoma for each of the samples that underwent laser 
capture microdissection.; a) FAM83H-AS1, b) PVT1, c) UCA1, d) H19, e) FER1L4, f) 





There was significantly decreased expression of FAM83H-AS1 in colon 










There was significantly increased expression of PVT1 in colon adenocarcinoma 









There was significantly decreased expression of UCA1 in colon adenocarcinoma 









There was no difference in the expression of H19 in colon adenocarcinoma cells 









There was no difference in the expression of FER1L4 in colon adenocarcinoma 









There was significantly increased expression of GAS5 in colon adenocarcinoma 









There was significantly increased expression of ZFAS1 in colon adenocarcinoma 






were significantly downregulated in the colon adenocarcinoma samples compared to 
normal colon epithelium (Fold regulation= -3.68, p<0.001 and fold regulation= -4.85, 
p<0.001). 
 
2. Verification of cell line lncRNA expression and baseline lncRNA 
expression in 3 colon adenocarcinoma cell lines 
 The Cancer Cell Line Encyclopedia is a public bioinformatics repository from the 
Broad Institute that has RNA-sequencing data on cancer cell lines.118 We employed this 
database to examine for expression of the selected lncRNAs in each of the three cell lines 
(Table 6). This database was also used to verify the given cell lines as an appropriate 
model for studying the in vitro function of the specific lncRNAs. The three cell lines used 
were: HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown). Both GAS5 and 
ZFAS1 had considerable expression in all 3 of the cell lines, as compared to the other 
lncRNAs.  
By utilizing the RNA-sequencing data from The Cancer Genome Atlas, we sought 
to examine the expression of lncRNAs which were confirmed to be significantly 
increased in colon cancer compared to normal colon epithelium, and that were 
significantly represented in our cell line models. We therefore proceeded with the 





3. Cellular localization of lncRNAs in the 3 colon adenocarcinoma cell lines 
To further characterize the 3 selected lncRNAs, we examined their subcellular 
location in each of the cell lines. The Protein And RNA Isolation System (PARIS) kit 
was used for this purpose. This kit facilitates the separation of the nuclear compartment 
from the cytoplasmic compartment, which allows for the examination of RNA and/or 
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ZFAS1 was significantly increased in the cytoplasmic fraction compared to the 
nuclear fraction of all 3 cell lines (HT29: 76% vs. 24%, p=0.02, SW480: 84% vs. 16%, 
p=0.03, Caco2 77% vs. 23%, p=0.005) (Figure 19). Similarly, GAS5 was also 
significantly increased in the cytoplasmic fraction compared to the nuclear fraction in all 
3 cell lines (HT29: 79% vs. 21%, p=0.02, SW480: 84% vs. 16%, p=0.003, Caco2 77% 
vs. 23%, p=0.008) (Figure 20). In contrast, PVT1 was more expressed in the nuclear 
fraction compared to the cytoplasmic fraction (HT29: 87% vs. 13%, p=0.005, SW480: 
80% vs. 20%, p=0.1, Caco2 64% vs. 36%, p=0.004) (Figure 21). 
 
4. Efficiency and fold regulation of lncRNA knockdown in 3 colon  
adenocarcinoma cell lines  
The expression of the three lncRNAs was examined in each of the 3 cell lines 
following transfection with either ZFAS1 siRNA, PVT1 siRNA, GAS5 siRNA, or with 
non-targeting siRNA. In the HT29 cell line, there was efficient knockdown of both 
ZFAS1 and GAS5, but not PVT1 compared to cells transfected with non-target siRNA 
(Figure 22a-c). Accordingly, there was a significant decrease in expression of ZFAS1 and 
GAS5 compared to non-target siRNA (Fold regulation=  -2.95, p<0.001, Fold regulation= 
-4.75, p=0.002 respectively.) (Figure 22d) 
Similarly, in the SW480 cell line there was efficient knockdown of both ZFAS1 
and GAS5, but not PVT1 compared to cells transfected with non-target siRNA (Figure 




Figure 19. Subcellular distribution of ZFAS1 in each of the three colon adenocarcinoma 
cell lines. In each of the three cell lines, ZFAS1 was significantly increased in the 
cytoplasm (highlighted in blue) compared to that of the nucleus (highlighted in orange) 






Figure 20. Subcellular distribution of GAS5 in each of the three colon adenocarcinoma 
cell lines. In each of the three cell lines, GAS5 was significantly increased in the nucleus 
(highlighted in orange) compared to that of the cytoplasm (highlighted in blue) (HT29: 







Figure 21. Subcellular distribution of PVT1 in each of the three colon adenocarcinoma 
cell lines. In each of the three cell lines, PVT1 was significantly increased in the 
cytoplasm (highlighted in blue) compared to that of the nucleus (highlighted in orange) 






Figure 22. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to 
non-targeting siRNA in the HT29 cell line. There is significant knockdown of ZFAS1 (a) 
and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of 






compared to non-target siRNA (Fold regulation= -9.96, p<0.001, Fold regulation= -9.79, 
p<0.001 respectively.) (Figure 23d). 
Finally, in the Caco2 cell line there was efficient knockdown of both ZFAS1 and 
GAS5, but not PVT1 compared to cells transfected with non-target siRNA (Figure 24a-
c).  There was a significant decrease in expression of ZFAS1 and GAS5 compared to 
non-target siRNA (Fold regulation= -5.28, p<0.001, Fold regulation= -7.18, p=0.01 
















Figure 23. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to 
non-targeting siRNA in the SW480 cell line. There is significant knockdown of ZFAS1 
(a) and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of 







Figure 24. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to 
non-targeting siRNA in the CACO2 cell line. There is significant knockdown of ZFAS1 
(a) and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of 








Utilizing the TCGA database, we have identified that 7 lncRNAs showed 
increased expression in colon adenocarcinoma compared to normal colon epithelium. We 
aimed to verify the expression of each of the selected lncRNAs in clinical samples that 
underwent laser capture microdissection. Three of the lncRNAs were increased in 
expression compared to the paired normal colon epithelium sample, which importantly 
matched the direction of expression identified from The Cancer Genome Atlas. In 
contrast, two of the lncRNAs were significantly decreased in the colon adenocarcinoma 
sample compared to that of the paired normal colon epithelium. Furthermore, all 3 cell 
lines had robust expression of ZFAS1, GAS5, and PVT1, which were chosen for further 
investigation. Upon examining the subcellular location of each of these 3 lncRNAs, 
ZFAS1 and GAS5 were located mainly in the cytoplasm compared to PVT1, which was 
located mainly in the nucleus. When the efficiency of knockdown with a siRNA against 
each of the three lncRNAs was examined, robust knockdown was only observed with 
ZFAS1 and GAS5. 
It is important to characterize and validate the expression of molecules from high-
throughput sequencing databases with institutional clinical samples. As previously 
mentioned, molecules can have differential expression depending on the intra-tumoral 
location (e.g. surface of the colon vs. the invasive border of the tumor), or the cell from 
which the RNA is expressed (e.g. immune cell in the microenvironment vs. colon 
adenocarcinoma cell). Interestingly, UCA1 was significantly decreased in our 
institutional samples which support Jahaingiri et al. who hypothesize that UCA1 is 
expressed by cancer associated fibroblasts as opposed to colon adenocarcinoma cells.94 
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In addition, the cellular localization of lncRNAs helps to define their function. 
RNA interference typically occurs in the cytoplasm of a cell, as the RISC complex and 
the other machinery for this function occurs in the cytoplasm. microRNAs and small 
interfering RNAs both mediate their function in an RNA interference-based mechanism, 
to either repress the translation of a mRNA or to degrade the transcript in the cytoplasm. 
Therefore, one would suspect that a lncRNA located in the cytoplasm would be more 
likely to perform its principal function in the cytoplasm, such as that of a competitive 
endogenous RNA function. This hypothesis is supported by the results of the knockdown 
experiments, as PVT1, which is a nuclear located lncRNA does not have significant 
knockdown with transfection of siRNA. This is in contrast to that of both ZFAS1 and 
GAS5, which are located in the cytoplasm and have robust knockdown with siRNA. The 
further examination of PVT1 would require an alternative method to investigate its 
function in vitro, such as the use of CRISPR-based technology.  
As both GAS5 and ZFAS1 were significantly increased in expression in colon 
adenocarcinoma, compared to normal colon epithelium, and there was reproducible 
knockdown of both GAS5 and ZFAS1 with siRNA transfection, we selected ZFAS1 and 



















The lncRNAs from previous chapters selected for further in vitro investigation were 
GAS5 and ZFAS1. Both lncRNAs were increased in colon cancer compared to normal colon 
epithelium and were located in the cytoplasmic cellular compartment. This suggested that both 
lncRNAs had a competitive endogenous RNA mechanism. Therefore, as a means of delineating a 
preferred candidate, we aimed to characterize the function of these lncRNAs in terms of their 
effect on colon cancer phenotype.  
As previously mentioned, both lncRNAs were predicted to mediate an effect on cellular 
proliferation and migration. We hypothesized that at least one of these lncRNAs would mediate a 
larger effect on cellular proliferation, and that from these data, a single candidate lncRNA could 
be identified to investigate cellular migration. Although lncRNAs may be predicted to have an 
effect on cellular function, a large number of these molecules do not mediate an effect on cellular 
function. Therefore, the purpose of these experiments was to verify and validate the effect of 
lncRNA knockdown on cellular function, with lncRNAs that were identified to be increased in 




1) Knockdown of ZFAS1, but not GAS5, leads to reduced cell proliferation in colon cancer cell 
lines 
Colon cancer cell lines, HT29 (Stage III) SW480 (Stage II), and Caco2 (Stage Unknown), were 
transfected with ZFAS1 siRNA, GAS5 siRNA, or non-targeting siRNA to examine for 
differences in cellular proliferation. The cell viability of each transfected well was checked for 
cell viability and were >90-95% for all transfections. Cell viability demonstrated that all cells had 
Cells were transfected for 48 hours in 6-well plates, and then plated in 12-well plates to examine 
cellular proliferation. Cells counts were examined every 24 hours for five consecutive days.  
In both the HT-29 and the SW-480 cell lines, ZFAS1 knockdown led to reduced cellular 
proliferation compared to cells transfected with non-target siRNA (Figure 25a, 26a). In contrast, 
there was no difference in the cellular proliferation of the Caco2 cell line between cells 
transfected with ZFAS1 siRNA compared to non- target siRNA (Figure 27a).  
In all three cell lines, there was no difference in cellular proliferation of cells transfect with GAS5 
siRNA compared to non-target siRNA (Figure 25b, 26b, 27b).  
Therefore, we chose to focus the remainder of the in vitro experiments on the effect of ZFAS1 on 
cellular phenotype. 
 
2)  Knockdown of ZFAS1 leads to reduced migration of colon cancer cells 
All 3 colon cancer cell lines, HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown), 
were transfected with either ZFAS1 siRNA or non-target siRNA. Following transfection and 
plating for scratch analysis, photographs of the scratch were taken every 24 hours up to scratch 
closure or to 120 hours after the scratch was made.  
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Figure 25. Proliferation of the HT-29 cell line following transfection with a) ZFAS1 siRNA and 
b) GAS5 siRNA, compared to transfection with non-target siRNA.  
 
There is decreased proliferation of the SW-480 cell line with transfection of ZFAS1 siRNA 
compared to non-target siRNA at 96 hours (*P=0.02) and 120 hours (*P=0.02). There is also a 
significant decrease in the doubling time of the cells transfected with ZFAS1 siRNA compared to 
non-target siRNA (P=0.04). There was no difference in the proliferation of cells transfected with 






Figure 26. Proliferation of the SW-480 cell line following transfection with a) ZFAS1 siRNA and 
b) GAS5 siRNA, compared to transfection with non-target siRNA. 
 
There is decreased proliferation of the SW-480 cell line with transfection of ZFAS1 siRNA 
compared to non-target siRNA at 72 hours (*P=0.03), 96 hours (*P=0.03), and 120 hours 
(**P=0.02). There is also a significant decrease in the doubling time of the cells transfected with 
ZFAS1 siRNA compared to non-target siRNA (P=0.01). There was no difference in the 









Figure 27. Proliferation of the Caco2 cell line following transfection with a) ZFAS1 siRNA and 
b) GAS5 siRNA, compared to transfection with non-target siRNA. 
 
There was no difference in the proliferation of Caco2 cells transfected with ZFAS1 siRNA or 




As expected, ZFAS1 knockdown lead to decreased scratch closure in the HT29 cell line at 120 
hours (Figure 25a). In addition, ZFAS1 knockdown lead to decreased scratch closure in the 
SW480 and Caco2 cell line at 48 hours (Figure 25b, c).  
 
3) Knockdown of ZFAS1 leads to decreased transwell migration of colon cancer cells. 
The 3 colon cancer cell lines, HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown), 
were transfected with either ZFAS1 siRNA or non-target siRNA. After 24 hours’ incubation in a 
transwell insert, each insert was examined for migrated cells. There was decreased migration of 















Figure 28. Functional cell migration as measured by the scratch assay of the a) HT-29 cell line, b) 
SW480 cell line, and the c) Caco2 cell line with transfection of ZFAS1 siRNA compared to 
transfection with non-target siRNA. In all 3 cell lines there was slower scratch closure of cells 






















Figure 29. Transwell migration of the a) HT-29 cell line, b) SW480 cell line, and the c) Caco2 
cell line with transfection of ZFAS1 siRNA compared to transfection with non-target siRNA. In 
























These data demonstrate that ZFAS1 knockdown in colon cancer cell lines leads to a less 
aggressive phenotype than that of cells transfected with non-target siRNA. In two different 
functional experiments, ZFAS1 knockdown led to decreased cells growth and reduced cell 
migration. These results indicate that ZFAS1 may have a role as a mediator of cellular function in 
vitro. 
Interestingly, there was no difference in Caco-2 cell line proliferation. This is likely due 
to the fact that the doubling time of the Caco-2 cell line is quite slow at 62 hours. We were 
therefore unable to detect a difference in these slow growing cells over the time course of the 
experiment.126 In contrast, knockdown of ZFAS1 in the other two cell lines, HT-29 and SW-480, 
led to reduced cellular proliferation. 
There was more marked transwell migration of the SW480 cell line compared to the 
Caco-2 and HT-29 cell lines. This is an expected observation, as the SW480 cell line has a 
mesenchymal phenotype and has a Consensus Molecular Subytpe 4 classification.126 In contrast, 
the HT29 cell line is characterized by a more rapid proliferation than the SW-480 cell line. This 
too is an expected result, as the HT-29 cell line has an epithelial phenotype and has a Consensus 
Molecular Subtype 3 classification. 
Knockdown of GAS5 did not lead to a change in proliferation compared to non-target 
siRNA. GAS5 is typically described to have a tumor suppressor function. This may in part 
explain why knockdown did not lead to increased cell growth.129 Although GAS5 expression is 
significantly increased in colon cancer in The Cancer Genome Atlas database and this was 
validated in our institutional samples, another study on colorectal cancer found GAS5 to be 
reduced in expression compared to normal tissue.130  
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The results of these experiments indicate that ZFAS1 is a good target for further 



































ZFAS1 HAS A RECIPROCAL RELATIONSHIP WITH MIR-200B AND MIR-200C 
 
a)  Introduction 
 
 In our previous experiments, we demonstrated that knockdown of ZFAS1 leads to 
a decrease in cell proliferation and cell migration as measured by the proliferation assay 
and transwell migration and scratch assays respectively.  Furthermore, we demonstrated 
that ZFAS1 is predominantly located in the cytoplasm, which suggests that it carries out 
its principal mechanism there. These data suggest that ZFAS1 plays a role in the 
epithelial-mesenchymal transition of cancer cells. Additionally, ZFAS1 has recently been 
identified to have a complex role in tumor signaling in different cancers.111  
We propose that by manipulating ZFAS1 expression in our three colon cancer cell 
lines, that we will affect the expression of target miRNAs. These target miRNAs have 
been identified by using a bioinformatics predication tool, and have also been 
experimentally verified in the literature through positive luciferase reporter assays or 
RNA pulldown assays. Utilizing siRNA that target against ZFAS1, we hypothesize that 
we will see a reciprocal increase in expression of the target miRNAs. As further evidence 
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to support this, we hypothesize that use of identified miRNA mimics will lead to a 
reciprocal decrease in ZFAS1 expression. The rationale for these experiments is to verify 
the interaction between ZFAS1 and the experimentally verified miRNA targets to help 
describe the signaling pathway with which ZFAS1 is associated. 
 
b) Results 
 lncRNA: miRNA Bioinformatics Prediction  
  LncBase (http://carolina.imis.athena-
innovation.gr/diana_tools/web/index.php?r=lncbasev2%2Findex-experimental) is a 
bioinformatics tool containing algorithmically predicted and experimentally verified 
miRNA targets for lncRNAs.131 This program functions by entering ENSEMBL ID codes 
for a given lncRNA or entering the miRBase ID code for a miRNA. This experimentally 
verified tool was employed to identify targets for ZFAS1. The original citing literature 
was identified. Five miRNA targets were identified from the LncBase program (Figure 















ZFAS1 binds to each of the miRNA at different sites along the transcript length.  
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Table 7- Literature reported microRNA interactions for the lncRNA ZFAS1 
lncRNA miRNA Literature citation 
Method of experimental 
verification 
ZFAS1 
miR-200b Liu G. et al132 
Zhang F et al133 
RNA immunoprecipitation 
RNA pulldown assay 
miR-200c Liu G. et al132 RNA immunoprecipitation 
miR-150 Xia B. et al134 
Li T. et al135 
Wu T. et al136 
Chen X et al.137 
Luciferase reporter assay 
RNA pulldown assay 
RNA pulldown assay 
RNA pulldown assay 
miR-484 Xie S et al.138 RNA immunoprecipitation 
miR-27a Ye Y et al.139 RNA pulldown assay, 











miRNA expression following ZFAS1 siRNA transfection 
miRNA expression was analyzed over three time points; 24, 48, and 72 hours. ZFAS1 
knockdown was verified using qRT-PCR. In the HT29 cell line, miR-200b was 
significantly increased at 24 (Fold change= 3.34, p=0.011) and 48 hours (Fold 
change=2.28, p=0.012) after transfection with ZFAS1 siRNA. miR-200c was also 
significantly increased in expression at 24 hours (Fold change= 2.19, p=0.038) after 
transfection with ZFAS1 siRNA. miR-27a was significantly increased in expression after 
48 hours (Fold change =6.70, p=0.020). There was no difference in the other miRNA at 
the time points examined (Figure 28). In the SW480 cell line, miR-200b was increased at 
24 hours (Fold change=6.69, p=0.005) and at 48 hours (Fold change= 1.88, p=0.022) 
after transfection with ZFAS1 siRNA. In addition, miR-200c was increased at 24 hours 
(Fold change= 6.53, p=0.010) and 48 hours (Fold change=1.80, p=0.025) after 
transfection. Similar to the HT29 cell line, there was no difference in the other miRNA 
examined at the time points. (Figure 29)  
ZFAS1 expression following miR-200b and miR-200c mimic transfection 
ZFAS1 expression was measured over the same three time points; 24, 48, and 72 hours 
after transfection of miR-200b and miR-200c mimics. In the HT29 cell line, transfection 
with miR-200b mimics and miR-200c mimics resulted in decreased ZFAS1 expression at 
48 hours after transfection (Fold change= -2.49, p=0.005 and Fold change= -3.60, 
p=0.002 respectively) (Figure 30). Similarly, transfection with miR-200b mimics and 
miR-200c mimics in the SW480 cell line resulted in decreased ZFAS1 expression at 48 
hours after transfection (Fold change= -2.24, p=0.03 and fold change= -2.21, p=0.007 
respectively) (Figure 31). 
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Figure 31. Expression of selected miRNA in the HT29 cell line following ZFAS1 siRNA 





Figure 32. Expression of selected miRNA in the SW480 cell line following ZFAS1 






Figure 33. Expression of ZFAS1 in the HT29 cell line following; a) miR-200b mimic 






Figure 34. Expression of ZFAS1 in the SW480 cell line following; a) miR-200b mimic 







Transfection with miR-200b and miR-200c mimics produces the same phenotype as cells 
transfected with ZFAS1 siRNA 
As a proof of concept to demonstrate the relationship between miR-200b, miR-
200c, and ZFAS1, we performed a scratch assay and transwell migration assay 
comparing cells transfected with miR-200b and miR-200c mimics compared to negative 
control.  
As expected, cells transfected with both miR-200b and miR-200c mimics had 
slower scratch closure compared to non-target siRNA, in the HT29 cell line (p<0.001, 
and p=0.004 respectively) (Figure 32). There was also decreased transwell migration of 
cells transfected with miR-200b and miR-200c mimics compared to non-target siRNA 
(both p=0.031) (Figure 33). 
In the SW480 cell line, there was also a slower scratch closure in cells transfected 
with mi-200b and miR-200c mimics compared to negative control (p=0.002 and p<0.001 
respectively) (Figure 34). Similarly, there was decreased transwell migration of cells 
transfected with miR-200b and miR-200c mimics compared to negative control (p=0.009 








Figure 35. There was decreased scratch closure of HT29 cells transfected with miR-200b 












Figure 36. There was decreased transwell migration of HT29 cells transfected with miR-











Figure 37. There was decreased scratch closure of SW480 cells transfected with miR-




Figure 38. There was decreased migration of SW480 cells transfected with miR-200b and 












The results of these experiments support the hypothesis that ZFAS1 directly binds to 
miR-200b and to miR-200c. ZFAS1 knockdown with siRNA leads to increased 
expression of the two miR-200 family members at two time points, and transfection with 
miR-200b and miR-200c mimics leads to decreased ZFAS1 expression. Interestingly, 
changes in the other miRNA targets were not consistently observed following ZFAS1 
knockdown. 
The changes in RNA expression occur at 24-48 hours after transfection when using 
siRNA and miRNA mimics to regulate gene expression. This is the timeframe in which 
changes of RNA expression are expected to occur when transfecting with these 
molecules. 
The miR-200 family is a well-described mediator of EMT and as a proof of concept, the 
functional experiments for migration demonstrated that miR-200b and miR-200c both 
lead to decreased migration. As previously mentioned, ZFAS1 knockdown also leads to 
decreased cell migration, and when considering that ZFAS1 has a reciprocal relationship 
with miR-200b and miR-200c, this suggests that they may share a common signaling 
pathway through which this effect is mediated. 
Consequently, this relationship was chosen for further study. These results support the 
competitive endogenous RNA hypothesis, in that ZFAS1 can act as a “molecular sponge” 









EFFECT OF ZFAS1 EXPRESSION ON THE ZEB1/E-CADHERIN, VIMENTIN TARGET 
SIGNALING PATHWAY 
 
a)  Introduction 
 
In the previous chapter, we demonstrated that ZFAS1 has a reciprocal relationship both 
miR-200b and miR-200c. When these results are considered in relation to the phenotypic results 
of decreased migration with ZFAS1 knockdown, these effects may be regulated through miR-
200/ZEB1/E-Cadherin, vimentin signaling.  
The miR-200 family is a well described major regulator of epithelial-mesenchymal 
transition (EMT).40 This is a critical factor involved in cancer metastasis. Loss of miR-200 family 
expression is observed at the invasive borders of colorectal cancer pathology specimens34  and is 
associated with adverse clinical outcomes.40 The miR-200 family does have a dichotomous role 
of also increasing cancer proliferation through different signaling pathways.53,140  
The signaling pathway through which ZFAS1 is associated with the miR-200 family has 
not, however, been completely defined. We hypothesized that ZFAS1 knockdown would lead to 
decreased expression of ZEB1. Furthermore, to validate the phenotypic results observed, we 
hypothesized that ZFAS1 knockdown would lead to an increase in an epithelial marker, E-
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Cadherin, and a decrease in a mesenchymal marker, Vimentin. The rationale for these 
experiments is to validate an associated signaling pathway through which ZFAS1 and miR-200b 





ZFAS1 knockdown leads to decreased ZEB1 RNA and protein expression 
After successful transfection of the HT-29 cell line with ZFAS1 siRNA and non-target 
siRNA there was significant decrease in ZEB1 mRNA expression compared to non-target siRNA 
(Fold regulation= -2.68, p=0.031) (Figure 39). As also expected, transfection with miR-200b and 
miR-200c mimics leads to decreased ZEB1 mRNA compared to non-target siRNA (Fold 
regulation= -3.19, p=0.03, and fold regulation= -1.82 p=0.04). (Figure 39)  
As a further proof of concept, there was a significant decrease in ZEB1 protein 
expression as examined by western blots in cells transfected with ZFAS1 siRNA compared to 
non-target siRNA (Figure 40). 
Similarly, in the SW-480 cell line, there was a significant decrease in ZEB1 mRNA 
expression after transfection with ZFAS1 siRNA compared to cells transfected with non-target 
siRNA (Figure 3). Transfection with miR-200b and miR-200c mimics also lead to decreased 
ZEB1 gene expression compared to non-target siRNA (Figure 41).  
When ZEB1 protein expression was examined with western blotting there was a 
significant decrease in expression in cells transfect with ZFAS1 siRNA compared to non-target 




ZFAS1 knockdown leads to decreased Vimentin protein expression 
To further support the functional data described in an earlier chapter, indicating that 
ZFAS1 is associated with EMT, we examined for differences between cells transfected with 
ZFAS1 siRNA compared to non-target siRNA. In the HT-29 cell line there was a significant 
decrease in vimentin with ZFAS1 knockdown compared to non-target siRNA. (Figure 43a) 
Similarly, in the SW480 cell line, there was a significant decrease in vimentin with ZFAS1 
knockdown compared to non-target siRNA (Figure 43b). 
ZFAS1 knockdown leads to increased E-Cadherin expression 
 As expected, HT29 cells transfected with ZFAS1 siRNA had significantly increased E-
cadherin expression compared to cells transfected with non-target siRNA. (Figure 44a) There was 
a significant increase in E-cadherin expression in the SW480 cells transfected with ZFAS1 













Figure 39.  ZEB1 gene expression in the HT-29 cell line following transfection with ZFAS1 
siRNA, miR-200b mimics, and miR-200c mimics compared to non-target siRNA. There is 









Figure 40. ZEB1 protein expression in the HT29 cell line in cells transfected with ZFAS1 siRNA 
or non-target siRNA. There is significantly decreased ZEB1 expression following transfection 














Figure 41. ZEB1 gene expression in the SW480 cell line following transfection with ZFAS1 
siRNA, miR-200b mimics, and miR-200c mimics compared to cells transfected with non-target 










Figure 42. ZEB1 protein expression in the HT29 cell line in cells transfected with ZFAS1 siRNA 
or non-target siRNA. There is significantly decreased ZEB1 expression following transfection 














Figure 43. Vimentin expression in the HT29 and SW480 cell lines transfected with ZFAS1 
siRNA or with non-target siRNA. There is decreased vimentin expression in both cell lines 








Figure 44. E-Cadherin expression in the HT29 and SW480 cell lines transfected with ZFAS1 
siRNA or with non-target siRNA. There is increased E-cadherin expression in both cell lines 











The results of these experiments indicate that ZFAS1 is associated with an effect on 
ZEB1 RNA and protein expression, which is a direct target of miR-200b and miR-200c. 
Furthermore, ZFAS1 regulates E-Cadherin and vimentin expression, which are both important 
proteins in EMT. When these results are considered in the context of the previous experiments 
indicating that ZFAS1 has a direct interaction with the miR-200 family, and that ZFAS1 
knockdown leads to decreased migration, we concluded that ZFAS1 knockdown was associated 
with EMT through the ZEB1/E-Cadherin, Vimentin signaling cascade.  
From RNA-sequencing data in the Cancer Cell Line Encyclopedia, there is relatively low 
expression of ZEB1 in both the HT29 and SW480 cell line, which is reflected in the western blot 
data shown in this chapter. For ZEB1 expression, a larger protein load (100ng) was used to 
facilitate band detection in both cell lines.  
There is robust E-Cadherin expression and relatively lower vimentin in the HT29 cell line 
when examining the western blotting data. The HT29 cell line is an epithelial-like cell line126, 
which is reflected in its Consensus molecular subtype 3 classification, and in its RNA-sequencing 
profile as assessed by the Cancer Cell Line Encyclopedia.118 In contrast, there is more robust 
vimentin expression and relatively lower E-Cadherin expression in the SW480 cell line when 
examining the western blotting data. This, again, is reflected in its mesenchymal Consensus 
Molecular Subtype 4 classification126, and its RNA-sequencing profile as assessed by the Cancer 
Cell Line Encyclopedia.118 
Typically, EMT is associated with decreased migration and increased proliferation, and 
many of the studies that investigate the miR-200 family as a regulator of EMT recapitulate these 
results.40 However, as previously mentioned, some studies have indicated that it may also lead to 
increased proliferation through alternative signaling pathways.52,53 The presented data suggest 
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that ZFAS1 knockdown was associated with a signaling pattern consistent with EMT in that there 
is changes in ZEB1, E-Cadherin, and Vimentin expression. A recent study investigating ZFAS1 
also demonstrated that it regulated migration and proliferation through another signaling cascade, 
miR-150-5p/VEGFA.137 
In the context of the previous chapters, ZFAS1 knockdown is consistent with both the 





























DISCUSSION AND CONCLUDING REMARKS 
 
We hypothesized that the use of an RNA-sequencing data set to compare the entire 
transcriptome of colon adenocarcinoma tissue to paired normal colon epithelium tissue would 
allow us to investigate specifically differentially expressed lncRNAs. As a number of studies 
have shown that lncRNAs can have different roles in different cancers, it is important to 
investigate their specific role in colon adenocarcinoma. This improves the understanding of 
cellular signaling, and allows for the identification of potential therapeutic targets.  
Here, we identify that lncRNA ZFAS1 is increased in colon adenocarcinoma compared to 
normal colon epithelium, and that ZFAS1 is principally located in the cytoplasm compared to the 
nucleus of 3 colon adenocarcinoma cell lines. To further characterize ZFAS1, we performed a 
number of different functional experiments, which demonstrated that ZFAS1 knockdown leads to 
reduced cellular proliferation and migration. From a mechanism perspective, ZFAS1 was 
predicted to have a direct binding relationship with miR-200b and miR-200c. As expected, 
ZFAS1 had a reciprocal relationship with both miR-200b and miR-200c.  Finally, ZFAS1 was 
able to regulate ZEB1 expression, and was able to regulate the epithelial marker E-Cadherin and 
the mesenchymal marker, Vimentin. The results of these experiments indicate that ZFAS1 is a 








Figure 45. Summary of dissertation findings. The lncRNA ZFAS1 which was identified to be differentially expressed from the 









There are variable results with the examination of ZFAS1 in the literature.111 ZFAS1 has 
previously been shown to have a tumor suppressive function in breast cancer by decreasing both 
cell proliferation and migration.141,142 Examination of ZFAS1 in hepatocellular carcinoma has 
shown that it can have both a tumor suppressive and oncogenic function through different 
mechanisms. It can act as a tumor suppressor by regulating the methylation of miR-9 in 
hepatocellular carcinoma143, but can also promote cancer metastasis through binding of miR-
150.135 However, the majority of studies demonstrate that ZFAS1 has an oncogenic function, in 
that many of the studies indicate that ZFAS1 can regulate both proliferation and migration.134,144.  
Recently, Chen et al. reported that ZFAS1 could regulate proliferation, migration, and invasion in 
colorectal cancer.137 They showed that ZFAS1 could mediate this through indirect regulation of 
VEGFA through direct binding with miR-150. The results of our experiments support the 
functional data reported by Chen et al, in that ZFAS1 knockdown leads to decreased proliferation 
and migration.  
Nevertheless, we report a novel signaling association between ZFAS1 and miR-200b and 
miR-200c. Interestingly, we also investigated the interaction with miR-150, but we did not find a 
reciprocal change in expression, although Chen et al. reported that miR-150 had a direct binding 
interaction with ZFAS1 in the HCT116 cell line. The HCT116 cell line is also microsatellite 
instable and has lower expression of ZFAS1 than any of the three cell lines that we selected for 
investigation.118,145 The HCT116 cell line may have a different transcript expression profile 
compared to our three cell lines, which may account for this lack of a difference, however this 
does remain unclear and requires further investigation.  
Nevertheless, both sets of data support the concept that lncRNAs can have multiple 
mechanisms of action, through different signaling cascades. This attribute has been described as 
both a positive and negative aspect of their potential utility.146,147 On one hand, the multiple 
mechanisms of action could reduce cancer aggressiveness through a number of different signaling 
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pathways which has clear major benefits. However, as previously noted, lncRNAs have been 
shown to have differential functions in different cancers, and often the exact mechanism through 
which they mediate their effect can be difficult to discern. Therefore, considerable study of a 
single lncRNA would be required prior to a potential clinical use.  Overall, non-coding RNAs are 
being investigated as a small molecule therapeutic strategy for different diseases. There are a 
number of clinical trials exploring the use of microRNA and siRNA technology as a therapeutic 
strategy.148 For example, miR-122 is a critical molecule in the survival of the hepatitis C virus in 
the liver. As such, a novel small molecule targeting miR-122 has been shown to be effective in 
reducing hepatitis C virus RNA levels in a phase 2 clinical trial.149 Similarly, a specific siRNA 
directed against procollagen alpha delivered in lipid nanoparticles has shown to be effective in 
resolving liver fibrosis in a murine model suggesting its potential therapeutic use.150 . Another 
siRNA targeting the respiratory syncytial virus has been shown to reduce the risk of bronchiolitis 
obliterans in patients post lung transplant.151   In the future lncRNAs and other non-coding RNAs 
may have a major role in the therapeutic management of different diseases. 
Many studies demonstrate that lncRNAs can be regulated by miRNA through the 
competitive endogenous RNA mechanism, but few have demonstrated alternative regulators. SP1 
transcription factor, SP1, has been shown to transcriptionally increase  ZFAS1 in a number of 
different cancer types.111 Interestingly, the transcription factors that regulate protein coding genes 
are the same as those for non-protein coding genes.152 This suggests there is a further layer of 
complexity in studying the relationship between lncRNAs and other protein coding genes with 
modulation of specific transcription factors. 
There are a number of challenges in studying lncRNAs, as they can have a diverse array of 
mechanisms of action. However, their cellular location is an important indicator of their 
mechanism of action. After selection of 3 lncRNAs for further investigation, only two (GAS5 and 
ZFAS1) were significantly represented in the cytoplasm of the cell, which is in contrast to that of 
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PVT1 which was significantly expressed in the nucleus. This does suggest that both GAS5 and 
ZFAS1 have a cytoplasmic mechanism of action, namely a competitive endogenous RNA 
function, such as acting as a miRNA sponge. Although PVT1 is predicted to have miRNA targets, 
it is more likely that its principal function is that of a nuclear mechanism of action, through DNA 
repair and rearrangements and interacting with the proto-oncogene MYC, which is supported by 
studies in the literature153,154 In addition, there is a challenge when examining lncRNAs, as siRNA 
technology has minimal effect on lncRNAs located in the nucleus as the cellular machinery to 
perform RNA interference is located in the cytoplasm, and siRNA has relatively poor function 
against nuclear located lncRNAs.155,156  
 There are some areas of needed further investigation that are highlighted by the results of 
these experiments. TGF-β is a major inducing agent of EMT51, and recent studies have 
demonstrated that it can be secreted by macrophages and other immune cells in the tumor 
microenvironment.157 The role of lncRNAs involved in promoting a less aggressive, epithelial 
phenotype, could be investigated in the context of cytokines secreted in the tumor 
microenvironment. This could be achieved through the use of transwell chambers, or by treating 
colon adenocarcinoma cell lines with cultured macrophage secretions, as performed by Jahangiri 
et al.94 Although our study demonstrates the role of ZFAS1 in signaling through regulation of 
miR-200b and miR-200c, ZFAS1 has been shown to interact with a number of other miRNAs.  
This indicates that there is significant investigation required to fully delineate the function of 
ZFAS1 and other lncRNAs prior to their clinical use.  
 Although we selected lncRNAs that are increased in expression in colon cancer compared 
to normal colon epithelium, there are a large number of lncRNAs that are downregulated in 
expression. Due to their large size, stable transfection is challenging, but some investigators have 
suggested the use of CRISPR-activation technology to stably increase the expression of a 
lncRNA in vitro.158,159 There are 5 members of the miR-200 family and we have restricted our 
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study to two of these, miR-200b and miR-200c as they have been experimentally verified to 
interact with ZFAS1. Although miR200b, miR-200c, and miR-429 are part of the same functional 
cluster, we did not examine the role of miR-429 as it appears not to be an experimentally 
validated target of ZFAS1. Further studies could investigate the role of other members of the 
miR-200 family in relation to ZFAS1. As previously mentioned many target molecules can be 
regulated by multiple lncRNAs, but when this is considered in the context that lncRNAs can 
regulate multiple different molecules, it will become important to study lncRNAs in signaling 
networks. For example, both SPRY4-IT1 and SNHG6 both target miR-101 to regulate ZEB1 to 
mediate EMT, but they have not been investigated together in the context of modulating one of 
them.69,70  
There are a number of limitations to this work. Although ZFAS1 knockdown is 
associated with both functional changes and reciprocal changes in the miR-200/ZEB1/E-cadherin, 
Vimentin signaling pathway, we have not definitively shown that that ZFAS1 is a regulator of 
this signaling cascade. Further experiments, such as a dual knockdown of both ZFAS1, and miR-
200b or miR-200c, are required to investigate the role of ZFAS1 as a regulator of this signaling 
pathway. As previously mentioned, lncRNAs can mediate an effect on a number of different 
signaling pathways and we focused on a single signaling pathway to help delineate the 
mechanism of action of ZFAS1. Therefore, further work is required to investigate the other 
pathways through which ZFAS1 may be mediating an effect on colorectal carcinogenesis. While 
the transcription factor SP1 is a known upstream regulator of ZFAS1, other reasons for the 
increased expression of ZFAS1, such as copy number amplification were not explored.  
In conclusion, we identified a group of lncRNAs that were significantly increased in 
expression in colon adenocarcinoma compared to normal colon epithelium in an RNA-
sequencing data set. We verified that a lncRNA ZFAS1 can regulate EMT through a reciprocal 
interaction with both miR-200b and miR-200c. Knockdown of ZFAS1 can lead to a less 
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aggressive phenotype in colon cancer cell lines, reduction in the mesenchymal marker, Vimentin, 
and an increase in the epithelial- marker, E-cadherin. This indicates that ZFAS is a major 
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EMT Epithelial-Mesenchymal Transition 
lncRNA long non-coding RNA 
miRNA microRNA 
mRNA messengerRNA 
CRC colorectal cancer  
miR microRNA 
ZEB1,2 Zinc Finger E-Box Binding Homeobox 1,2 
E-cadherin Epithelial cadherin 
XIST X-Inactive Specific Transcript 
H19 Imprinted Maternally Expressed Transcript 
MET Mesenchymal-epithelial transition 
UICLM Upregulated In Colorectal cancer and Liver Metastasis 
N-BLR primate specific non-coding transcript 
XIAP X-linked Inhibitor of Apoptosis Protein 
SPRY4-IT1 Sprouty RTK signaling antagonist 4-Itronic Transcript 1 
Wnt Wingless/Integrated 
β -catenin Beta-catenin 
PlncRNA-1 “CBR3”-Carbonyl Reductase 3 
TUG1 Taurine Upregulated 1 
MMP9 Matrix Metalloproteinase-9 
PGRN Progranulin 
KIAA119                    Cell Migration Inducing Hyaluronidase 1 
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UCA1                         Urothelial Cancer Associated 1 
mTOR                        mammalian Target of Rapamycin  
TWIST1 Twist related protein 1 
CHRF Cardiac Hypertrophy Related Factor 
GALNT1 Polypeptide N-acetylgalactosaminyltransferase 1 
SNHG7 Small Nucleolar RNA Host Gene 7 
MALAT1 Metastasis Associated Lung Adenocarcinoma Transcript 1 
EZH2 Enhancer of Zeste Homolog 2  
HOXD-AS1 “HAGLR” HOXD Antisense Growth-Associated Long Non- 
 Coding RNA 
AEG-1 Astrocyte Elevated Gene 1 
HIF1A-AS2 Hypoxia Inducible Factor 1 Alpha-Antisense RNA 2 
DNMT3A DNA Methyltransferase 3 Alpha  
HDAC Histone Deacetylase 
siRNA small interfering RNA 
CYTOR Cytoskeleton Regulator RNA 
CTD903 “DUXAP9” Double Homeobox A Pseudogene 9  
lncTCF7 long non-coding Transcription Factor 7 
PVT1 Pvt oncogene  
TGF- β Tumor Growth Factor Beta 
LINC001133 Long Intergenic Non-Coding RNA 001133 
SRSF-6 Serine/arginine Rich Splicing Factor 6 
JAK-STAT3 Janus Kinase Signal Transducer and Activator of Transcription 3 
BC200 Brain Cytoplasmic 200  
lncRNA AB073614 lncRNA AB073614 
CPS1-IT1 Carbamoyl-Phosphate Synthase 1 Intronic Transcript 1 
LC-1 Light Chain 1 
MAPK Mitogen Activated Protein Kinase 
ERK Extracellular signal-Related Kinases 
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BACNR  BRAF-Activated Non-Protein Coding RNA 
MEK Mitogen activated protein kinase kinase 
NNT-AS1 NAD(P) Transhydrogenase Antisense RNA 1 
SLC25A25-AS1 Solute Carrier Family 25 Member 25 
SLUG “SNAI2” Snail Family Transcription Repressor 2 
SNAIL “SNAI1” Snail Family Transcription Repressor 1  
SNGH15 Small Nucleolar RNA Host Gene 15 
lncRNA-ATB lncRNA Activated by TGF-β 
LINC00959 Long Intergenic Non-Coding RNA 00959  
FOXD2-AS1 Forkhead Box D2 Antisense RNA 1 
HOTAIR HOX Transcript Antisense RNA 
HOXA-AS2 Homeobox A cluster Antisense RNA 2 
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